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Abstract
Tetrodotoxin (TTX) and its analogues are produced by marine bacteria and have been detected in
marine bivalves and gastropods from European waters. The European Commission asked EFSA for a
scientiﬁc opinion on the risks to public health related to the presence of TTX and TTX analogues in
marine bivalves and gastropods. The Panel on Contaminants in the Food Chain reviewed the available
literature but did not ﬁnd support for the minimum lethal dose for humans of 2 mg, mentioned in
various reviews. Some human case reports describe serious effects at a dose of 0.2 mg, corresponding
to 4 lg/kg body weight (bw). However, the uncertainties on the actual exposure in the studies preclude
their use for derivation of an acute reference dose (ARfD). Instead, a group ARfD of 0.25 lg/kg bw,
applying to TTX and its analogues, was derived based on a TTX dose of 25 lg/kg bw at which no
apathy was observed in an acute oral study with mice, applying a standard uncertainty factor of 100.
Estimated relative potencies for analogues are lower than that of TTX but are associated with a high
degree of uncertainty. Based on the occurrence data submitted to EFSA and reported consumption days
only, average and P95 exposures of 0.00–0.09 and 0.00–0.03 lg/kg bw, respectively, were calculated.
Using a large portion size of 400 g bivalves and P95 occurrence levels of TTX, with exception of oysters,
the exposure was below the group ARfD in all consumer groups. A concentration below 44 lg TTX
equivalents/kg shellﬁsh meat, based on a large portion size of 400 g, was considered not to result in
adverse effects in humans. Liquid chromatography with tandem mass spectroscopy (LC–MS/MS)
methods are the most suitable for identiﬁcation and quantiﬁcation of TTX and its analogues, with LOQs
between 0.1 and 25 lg/kg.
© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the Panel on Contaminants in the Food Chain
(CONTAM Panel) was asked to deliver a scientiﬁc opinion on the risk related to the presence of TTX
and TTX analogues (TTXs) in marine bivalves and gastropods.
TTX is a hydrophilic toxin, produced by bacteria that can be found in certain ﬁsh species but also
marine gastropods and bivalves. There are no health-based guidance values for TTX worldwide and
also no maximum levels of TTX in seafood in the European Union (EU).
Altogether, 25 naturally occurring analogues of TTX have been detected and many of these have
also been shown to have toxicity potential. TTX is positively charged in neutral solutions. Under acidic
conditions, TTX exists as a mixture in equilibrium with the ortho ester, the lactone form, 4-epiTTX and
4,9-anhydroTTX.
Recently, TTX and some analogues have been detected in gastropods and bivalves from European
waters using liquid chromatography with tandem mass spectroscopy (LC–MS/MS) methods. The
CONTAM Panel concluded that these methods are the most suitable methods for identiﬁcation and
quantiﬁcation of TTXs. Besides, saxitoxins (STXs) may be included in the same analysis. Limit of
quantiﬁcation (LOQs) for TTX and analogues in marine bivalves, as reported by three Member States,
vary between 0.1 and 25 lg/kg.
The mouse bioassay is the most widely applied detection method for TTXs outside the EU.
However, this test cannot discriminate between TTX and its analogues and it can also not discriminate
TTXs from STXs. Cell-based methods and immunoassays can be used for screening but cannot identify
or quantify the different TTXs or discriminate between TTXs and STXs.
There is limited information about absorption and excretion of TTX and its analogues in humans
and no information has been identiﬁed on its distribution and metabolism. It is assumed that TTX is
rapidly absorbed in the human digestive tract, based on the short time span between ingestion and
onset of the symptoms seen in human poisoning cases. In human poisoning cases, TTX has been
detected in blood and urine of patients for several days after exposure.
TTX is acutely toxic in humans and in experimental animals. In humans, TTX exhibits its toxicity by
extracellular blockade of the channel pore of voltage-gated sodium channels (Nav). Thus, TTX affects
both action potential generation and impulse conduction, resulting in a blockade of the neuron action
potential and in muscle paralysis. This leads to a sequence of acute symptoms from perioral numbness
and paraesthesia, lingual numbness, early motor paralysis, incoordination, slurred speech to
generalised ﬂaccid paralysis, aphonia and ﬁxed/dilated pupils to hypoxia, hypotension, bradycardia,
cardiac dysrhythmias and unconsciousness and in the end death. Death is caused by respiratory failure
and cardiac collapse. There is no antidote against TTX poisoning.
In experimental animals, the effects that are observed upon acute exposure include skeletal muscle
fasciculations, apathy, lethargy, ataxia, ascending progressive paralysis and death.
Acute intraperitoneal (i.p.) and subcutaneous (s.c.) LD50 values in mice range from 9 to 12.5 mg/kg
body weight (bw). Upon intragastric application, much higher LD50 values of 232 and 532 mg/kg bw
have been identiﬁed.
A no observed adverse effect level (NOAEL) of 75 lg/kg bw was established by the authors in a
study with mice that received a single intragastric treatment. In this experiment, apathy was observed in
all animals treated with doses of 125 lg/kg bw and above, but not at levels of 75 and 25 lg/kg bw. At
higher doses, lethality was observed, i.e. at 250 lg/kg bw for four out of seven animals, at 500 lg/kg
bw for four out of ﬁve animals and at 1,000 lg/kg bw for three out of three animals. This shows a
relatively steep dose–response curve over a small dose range.
In the literature, a minimum lethal dose (MLD) of 2 mg is often mentioned for humans
(corresponding to 40 lg/kg bw in a 50-kg Japanese adult). However, the original source of this MLD
and the underlying data could not be retrieved. The doses at which TTX causes acute toxicity and
lethality in humans are unclear, but a series of human case reports are available that indicate that
acute poisoning can result from doses of 4–42 lg/kg bw or higher.
No subchronic or chronic studies on TTX in animals have been identiﬁed. TTX did not show any
genotoxic activity in a battery of good laboratory practice (GLP)-compliant in vitro and in vivo assays
conducted according to OECD guidelines.
Based on the pronounced toxicity of TTX upon acute exposure, the CONTAM Panel decided to
derive an acute reference dose (ARfD). Both the use of human data, extrapolation from data on STX
and the use of animal data were considered.
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Due to the limitations of the available human data related to the estimation of the ingested dose of
TTX, these data were not used to derive the ARfD, but they were used as supportive information.
Similarly, the ARfD for STX was used as supportive data. STX shows in humans similar effects and in
mice similar toxic potency both after i.p. and intragastric treatment. The mode of action of TTX and
STX is similar but with some differences in the afﬁnity for the different subtypes of Nav channels.
Apathy was the most sensitive endpoint in the oral acute study in mice, observed in none of the
animals at doses of 25 and 75 lg TTX/kg bw, but in all animals at 125 lg TTX/kg bw and above. At a
dose of 250 lg/kg bw and higher, lethality occurred. Whereas a benchmark dose (BMD) could not be
derived for apathy, a BMDL10 of 112 lg/kg bw for lethality was calculated, which is only slightly above
the NOAEL for apathy. Also, considering that with a group size of nine mice, applied at the dose of
75 lg/kg bw, it cannot be excluded that effects can occur, the next lower dose tested (25 lg/kg bw)
was used as the reference point. This resulted in an ARfD of 0.25 lg/kg bw after applying a standard
uncertainty factor of 100.
The dose of 25 lg/kg bw is 4.5-fold lower than the BMDL10 calculated for lethality. The CONTAM
Panel noted that the ARfD is 16-fold lower than the lowest dose at which severe effects have been
observed in humans (4 lg/kg bw) and is twofold lower than the ARfD for STX (0.5 lg/kg bw).
When i.p. injected in mice, many TTX analogues exert similar effects as TTX but no data are
available that allow derivation of NOAELs or lowest observed adverse effect levels (LOAELs). However,
values such as LD50, and LD99 upon i.p. application have been reported. These values have been used
to estimate relative potencies of a number of analogues, including the ones thus far detected in
bivalves and gastropods. The relative potencies calculated for 11-oxoTTX and 11-norTTX-6(R)-ol based
on i.p. LD99 results compared to LD100 for TTX are 0.75 and 0.17, respectively, while relative potencies
based on i.p. LD50 values in mice are 0.14 for 11-deoxyTTX and 0.19 for 11-norTTX-6(S)-ol. Relative
potencies calculated from lethal potencies in mice are 0.16 for 4-epiTTX and 0.02 for 4,9-anhydroTTX,
while the relative potency for 5,6,11-deoxyTTX is 0.01 based on comparison of the MLD with that for
TTX. For some of the analogues, these potencies are to some extent supported by in vitro tests with
the Neuro-2a bioassay. The Panel noted that the derivation of the relative potencies for TTX analogues
is associated with high uncertainties since the underlying methods and data are poorly described.
The ARfD of 0.25 lg/kg bw is therefore a group ARfD that should apply to TTX and its analogues
taking into account their relative potencies derived from a comparison with TTX using the most
appropriate parameters. For analogues detected thus far in marine bivalves and gastropods, these are
0.75 for 11-oxoTTX, 0.14 for 11-deoxyTTX, 0.19/0.17 for S/R 11-norTTX-(6)-ol, 0.16 for 4-epiTTX,
0.02 for 4,9-anhydroTTX and 0.01 for 5,6,11-deoxyTTX.
A total of 8,268 analytical results of 1,677 samples of bivalves were submitted to the European
Food Safety Authority (EFSA) by UK, Greece and the Netherlands. For all samples, analytical results
were provided for TTX, whereas 1,136 analytical results were provided for 4-epiTTX, 1,080 for 5,6,
11-trideoxyTTX, 1,080 for 11-norTTX-6-ol, 1,080 for mono-deoxyTTX, 1,135 for 4,9-anhydroTTX and
1,080 for 11-oxoTTX. Samples were taken between 2006 and 2016, including mussels, oysters,
cockles, clams, scallops and razor clams. No occurrence data were received for marine gastropods. In
1,544 (about 95%) of the samples, TTX was not detected or quantiﬁed, with LOQs ranging from 1 to
25 lg/kg. The upper bound median and 95th percentile levels reported to EFSA for TTX were 5.9 and
28 lg/kg. In most cases, this was based on raw meat, in some cases the digestive gland. Taking into
account the types of water molluscs one by one, the highest upper bound mean level was reported for
clams, 10.8 lg/kg; the highest 95th percentile level was reported for oysters, 79 lg/kg.
Due to the few quantiﬁed levels available, the relatively low levels of TTX analogues as compared
to TTX and low estimated relative potencies (RPs) for the detected analogues, they were not included
in the exposure assessment. Marine gastropods could not be included either, because no occurrence
data were provided.
Acute exposure assessments for TTX were carried out with two different approaches, namely i) by
using the consumption data in the EFSA Comprehensive database applying a probabilistic approach,
and ii) by using a large portion size of 400 g for bivalves. This value has been used as large portion
size in previous opinions on marine toxins. In the ﬁrst approach, exposure was calculated using the
probabilistic approach based on consumption days only.
Overall, the lower bound average acute exposure was zero while the upper bound was
0.01–0.09 lg/kg bw with the highest exposure calculated for the ‘elderly’ population. The highest
estimated 95th percentile exposure of 0.03 lg/kg bw occurred in the elderly, adults and adolescents.
However, only ﬁve out of 29 surveys allowed an estimate of the P95 exposure.
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Regarding the different types of marine bivalves, the highest mean exposure levels for clams,
mussels and oysters were 0.02, 0.03 and 0.09 lg/kg bw, respectively, whereas for the other bivalves,
average acute exposure was zero. The highest 95th percentile exposure was estimated for oysters,
being 0.08 lg/kg bw.
Using the large portion size of 400 g and P95 concentrations, the exposure ranged from 0.03 to
0.45 lg/kg bw, depending on the bivalve species.
The exposure estimates show that the average and 95th percentile acute exposure levels, either
based on reported consumption or on a large portion size of 400 g, did not exceed the group ARfD of
0.25 lg TTX/kg bw in any of the consumer groups except in case of consumption of a large portion of
oysters. This indicates no general concern for human health due to the consumption of marine
bivalves except for consumption of a large portion of oysters.
Based on a large portion size (400 g), an adult body weight of 70 kg and a group ARfD of 0.25 lg/kg
bw, the CONTAM Panel concluded that a concentration lower than 44 lg of TTX and/or the equivalent
toxic amount of its analogues per kg shellﬁsh meat is not expected to result in adverse effects in humans.
The Panel noted that the P95 of the occurrence data for all shellﬁsh is below this value. However, levels
above 44 lg/kg have been reported for both mussels and oysters indicating an occasional concern for
consumers of a large portion size of 400 g or larger.
It was not possible to perform a risk characterisation for marine gastropods because of limited
consumption data and a lack of occurrence data.
It is recommended that further data on the sources and critical factors leading to the accumulation
of TTX in marine bivalves and gastropods are collected.
There is also a need for further information on toxicokinetic and oral toxicity of TTX and its
analogues. Even though TTXs are acute toxic and there is no warrant of chronic effects, this should be
further investigated. Given the high uncertainties associated with derivation of the relative potencies of
TTX analogues, better description of the methods and data, or adequate data are needed to estimate
their relative potencies, preferentially after oral exposure. It should also be explored if STXs and TTXs
should be combined in one health-based guidance value regarding their similar toxic effects and mode
of action.
To provide more reﬁned exposure assessments, more data on both occurrence data of TTXs and
more consumption data of gastropods and bivalves are needed. More data are needed on the fate of
TTX and its analogues during cooking. Data on concentrations of TTX and its analogues should
preferably be obtained using EU approved and validated chemical-analytical methods. In addition,
certiﬁed standards and reference materials for TTX and its analogues are needed to improve the
quality of the occurrence data.
TTX in marine bivalves and gastropods
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
1.1.1. Background
Tetrodotoxins is the generic term for a group of toxins consisting of tetrodotoxins (=TTX) and
analogues such as 4-epi-TTX, 6-epi-TTX, 11-oxo-TTX and tetrodonic acid. Tetrodotoxin (TTX) is the
causative agent responsible for pufferﬁsh/fugu poisoning, a fatal marine poisoning found
predominantly in subtropical and temperate regions. It is found mainly in the organs of ﬁsh from the
Tetraodontidae family, as well as other marine species such as the blue-ringed octopus and
gastropods. The toxin and its structural analogues are thought to originate from a variety of marine
bacteria, including Vibrio spp.
Clinical effects include a range of neuromuscular symptoms (such as paraesthesia of lips and
tongue, dizziness and headache and gastrointestinal symptoms). Higher degree symptoms include
ataxia, incoordination, cardiac arrhythmias, seizures and respiratory failure, leading to death.
In the EU, TTXs were detected in the course of a non-fatal human intoxication following consumption
of a contaminated sea snail1 harvested in Portugal and consumed in Spain containing 315 mg TTX/kg
and 1,004 mg 5,6,11-trideoxyTTX/kg (Rodriguez et al., 2008; Fernandez-Ortega et al., 2010).
There has been no evidence of accumulation of TTX in bivalve molluscs grown in European waters
until recently, and the threat from this toxin group was deemed negligible within the European Union
(EU). However, detection of TTXs in European bivalve molluscs has been ﬁrst reported by the United
Kingdom for shellﬁsh in England harvested in 2013 and 2014 at a maximum level of 137 lg TTX/kg
(Turner et al., 2015), then by Greece in 2015 for samples obtained in 2012 at a maximum level of
223 lg TTX/kg (Vlamis et al., 2015). Moreover, a survey carried out in the Netherlands in 2015
revealed that TTXs can be found in mussels and oysters from Dutch production areas.
The current EU rules (Chapter V point 2 of Section VII of Annex III to Regulation 853/2004)
establish that live bivalve molluscs: ‘must not contain marine biotoxins in total quantities (measured in
the whole body or any part edible separately) that exceed the following limits:
a) for paralytic shellﬁsh poison (PSP), 800 lg/kg;
b) for amnesic shellﬁsh poison (ASP), 20 mg of domoic acid per kilogram;
c) for okadaic acid, dinophysistoxins and pectenotoxins together, 160 lg of okadaic acid
equivalents per kilogram;
d) for yessotoxins, 3.75 mg of yessotoxin equivalent per kilogram; and
e) for azaspiracids, 160 lg of azaspiracid equivalents per kilogram.’
TTXs are not included in the list of marine biotoxins to be tested neither at EU level nor at
international level (CODEX STAN 292-2008).
The European Food Safety Authority (EFSA), in its Scientiﬁc Opinion of the Panel on Contaminants
in the Food Chain on a request from the European Commission on marine biotoxins in shellﬁsh
(Question EFSA-Q-2006-065A), did not include this toxin in its evaluation.
1.1.2. Terms of Reference
Based in particular on the existing scientiﬁc literature, EFSA is requested to provide a scientiﬁc
opinion on:
1) the occurrence, including concentration data of TTX and TTX analogues in bivalve molluscs
and marine gastropods grown in EU and non-EU waters;
2) the toxicity for humans of TTX in bivalve molluscs and marine gastropods including: the
toxic doses (e.g. minimum lethal dose (MLD), lowest observed adverse effect level (LOAEL))
and if possible the establishment of health-based guidance values (HBGVs) (e.g. acute
reference dose (ARfD), tolerable daily intake (TDI));
3) the concentration of TTX and TTX analogues in bivalve molluscs and marine gastropods that
is not expected to lead to health risks;
1 Charonia lampas lampas.
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4) the most efﬁcient methods that could be used for the detection and quantiﬁcation of this
toxin group, including relevant parameters as limit of detection (LOD) and limit of
quantiﬁcation (LOQ) in relation to the concentration identiﬁed in Terms of Reference (ToR) 3.
In case insufﬁcient data are available for the EFSA’s assessment, EFSA should indicate which data
should be collected by the Member States in order to respond to this request.
1.2. Additional information
1.2.1. Sources and origin of TTX
Any concentrations of TTX or its analogues reported in the present opinion refer to fresh weight
material if not otherwise speciﬁed.
TTX and analogues were reported in gastropods (Rodriguez et al., 2008; Silva et al., 2012), oysters
and mussels (Turner et al., 2015; Vlamis et al., 2015). Many non-shellﬁsh species were reported to
contain TTX (Bane et al., 2014). Although the origin of TTX is known to be associated to bacteria of
the phylum Proteobacteria, containing Pseudomonas, Pseudoalteromonas and Vibrio, several phyla of
bacteria (Actinobacteria, Bacterioides, Firmicutes, Proteobacteria) were reported as potential TTX
sources (Jal and Khora, 2015). These bacteria were suggested to be linked to speciﬁc dinoﬂagellate
blooms, such as Prorocentrum minimum (Vlamis et al., 2015; Rodrıguez et al., 2017). The bacteria
that produce TTX (i.e. genus Bacillus, Shewanella, Roseobacter, Vibrio, Pseudomonas, Alteromonas,
Aeromonas, Nocardiopsis) are present in several species in the subcutaneous mucus, ovaries or in the
intestine (Wu et al., 2005; Noguchi et al., 2006; Bane et al., 2014).
1.2.2. Previous assessments
There are three previous assessments on TTX available from EU Member States. TTX has not
previously been considered by EFSA, the Scientiﬁc Committee on Food (SCF) or the Joint FAO/WHO
Evaluation Committee (JECFA).
Following the paper by Turner et al. (2015), RIKILT investigated shellﬁsh samples from Dutch
harvest areas for TTX in the end of 2015 (RIVM-RIKILT, 2015). A number of oyster and mussel
samples, collected during the summer period, showed detectable levels, with a maximum of 124.1 lg/kg
in oysters. The highest level in mussels was 33.3 lg/kg. All positive samples were derived from the
Oosterschelde in the south-west of the Netherlands, with levels above the LOQ of 10 lg/kg in 15 out
of 55 samples from that area. Subsequently, the National Institute for Public Health and the
Environment (RIVM)-RIKILT Front Ofﬁce on Food and Consumer Product Safety was asked by the
Netherlands Food and Consumer Product Safety Authority- Department for Risk Assessment and
Research (NVWA-BuRO) for a risk assessment. In the absence of a HBGV, a rapid scan of the literature
revealed that a dose of 2 mg was considered to be the MLD in several review papers, the initial ones
derived from Japan. The Hazardous Substances Data Bank2 mentions a range of 1–4 mg as the lethal
dose. It was noted that a dose of 0.2 mg was mentioned in some papers as a dose leading to adverse
effects but none of the papers mentioned the source of these ﬁgures, creating a high level of
uncertainty. In a human poisoning case in Spain, following consumption of a sea snail, an intake of
1.5 mg was estimated based on a suggested intake of 5 g of digestive gland of sea snail containing
300 mg TTX/kg (Rodriguez et al., 2008; Fernandez-Ortega et al., 2010). In addition to TTX, the gland
contained 1,000 mg 5,6,11-trideoxyTTX/kg. The patient recovered after artiﬁcial respiration. Overall, it
was concluded that 4 lg/kg body weight (bw) seemed to be at the lower end of the dose range
causing effects, with 10 lg/kg bw causing serious effects and 20–80 lg/kg bw being lethal without
proper treatment. However, because of the large uncertainty on the reported toxic doses, no ARfD
could be derived. Regarding differences in susceptibility between people, there are indications that this
applies to individuals with heart problems or diseases of the nervous system. The RIVM-RIKILT
FrontOfﬁce was also asked to suggest a safe level in shellﬁsh. Assuming that 4 lg/kg bw is a LOAEL, a
factor of 3 would be needed to derive a no observed adverse effect level (NOAEL) and a factor of 10
to account for differences between individuals. This would result in a safe intake level of 0.13 lg/kg
bw. Then, using the portion size of 400 g for a person of 60 kg bw, as applied by EFSA for other
marine biotoxins (EFSA CONTAM Panel, 2010a–d), a safe level in shellﬁsh would be 19.5 lg/kg. A
similar level was derived for a child of 20 kg bw consuming 130 g shellﬁsh. However, it was stressed
2 https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm
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that, regarding the uncertainties if the doses leading to adverse effects, it could not be excluded that
lower levels in shellﬁsh could also lead to effects. Based on this advice, NVWA-BuRO proposed to apply
a zero tolerance for TTX in shellﬁsh, which in practice meant that levels should be non-detectable with
a required LOQ of 20 lg/kg or lower.
The UK FSA risk assessment (FSA, 2017) concluded that, because of the acute toxicity of TTXs, it
would be appropriate to establish an ARfD, i.e. a dose level that would not be expected to result in
adverse effects following a single eating occasion or over the course of a day. However the available
data from human observations and from studies in experimental animals were not considered to
provide an adequate basis for deriving an ARfD. Therefore, while noting a need for a more
comprehensive literature search, a provisional approach was proposed based on the threshold of
toxicological concern (TTC), which is used as a priority setting tool for chemical substances in food
with no or few toxicological data. The TTC approach provides a framework for determining whether
exposure to a substance is so low that the probability of adverse effects is low, based on classiﬁcation
according to chemical structure (EFSA Scientiﬁc Committee, 2012). The FSA noted that Toxtree3
indicates that TTX (and its analogues) are not genotoxic and would fall into Cramer class III, which
means that an intake of less than 1.5 lg/kg bw per day for the sum of TTXs would not be expected to
be a safety concern. This value is half of the lowest dose at which symptoms have been reported, and
one-tenth of the minimum lethal dose. Hence when the mode of action for TTX toxicity is also taken
into consideration, it was concluded that this TTC value is a reasonable basis on which to undertake a
preliminary risk assessment. Based on the large portion size of 400 g shellﬁsh, identiﬁed in EFSA
CONTAM Panel (2010c), the concentration of TTX in shellﬁsh meat at which the TTC would not be
exceeded for EU adults weighing 70 kg is 0.262 mg/kg shellﬁsh meat. The age group with the highest
exposure to contaminant in food is commonly toddlers (1–3 years). However, taking into account that
toddlers would not be given bivalves in shell, it was considered unlikely that they would be given more
than a small number of mussels on any single occasion.
The Scientiﬁc Committee of the Belgian Federal Agency for the Safety of the Food Chain was asked
to set an action limit for TTX in bivalves (FAVV, 2016). The Committee reviewed the risk assessments
in the Netherlands and the UK resulting in safe levels in bivalves of 16.67 and 262 lg/kg meat,
respectively, based on a large portion size of 400 g. In Japan, a limit of 2,000 lg/kg is used for ﬁsh.
The Committee noted the large variation between the different levels and concluded that it is better to
wait for the risk assessment from EFSA. As a precautionary measure, it was advised to apply the LOQ
of the analytical method as action limit.
1.2.3. Chemistry
TTX is a heterocyclic compound that consists of a guanidinium moiety connected to an oxygenated
backbone that possesses a 2,4-dioxaadamantane structure with six hydroxyl groups (Chau et al.,
2011). Altogether 25 naturally occurring analogues of TTX have been detected (Bane et al., 2014).
TTX analogues found in pufferﬁsh as well as in gastropods and bivalves can be classiﬁed into four
groups (Yotsu-Yamashita et al., 2013):
1) analogues chemically equivalent to TTX (e.g. 4-epiTTX and 4,9-anhydroTTX),
2) deoxy analogues (e.g. 5-deoxyTTX, 11-deoxyTTX, 6,11-dideoxyTTX, and 5,6,11-trideoxyTTX),
3) (3) 11-CH2OH oxidised analogue (e.g. 11-oxoTTX),
4) C11 lacking analogues (e.g. 11-norTTX-6(S)-ol and 11-norTTX-6(R)-ol).
Table 1 shows nomenclature, molecular structures and weights and CAS numbers for the natural
occurring TTXs that have been reported to occur in bivalves and gastropods. (Bane et al., 2014; EFSA
database, see Section 3.3.2 Current occurrence).
TTX has a molecular weight of 319.1 g/M and the formula C11H17N3O8. TTX is hydrophilic and
under acidic conditions, TTX exists as a mixture in equilibrium of the ortho ester, the lactone form,
4-epi-TTX and 4,9-anhydroTTX (Nishikawa and Isobe, 2013). It is stated in several papers (e.g. Bane
et al., 2014; Turner et al., 2015; FAO/WHO, 2016) that TTX is heat stable but without reference to the
original data.
3 http://toxtree.sourceforge.net
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1.2.4. Legislation
Regulation (EC) No 853/20044 lays down speciﬁc rules for the hygiene in foodstuffs in the EU.
Chapter V of Section VII of Annex III to the regulation establishes that live bivalve molluscs placed on
the market for human consumption must not exceed limits for marine biotoxins. No such limits are
currently listed for tetrodotoxins. However, according to the regulation (section VIII, chapter V),
ﬁshery products derived from poisonous ﬁsh of the families Tetraodontidae, Molidae, Diodontidae and
Canthigas-teridae should not be marketed.
2. Data and methodologies
2.1. Data
2.1.1. Occurrence data
EFSA gathers data on the occurrence of chemical substances in food and feed at the EU level
through continuous collections and/or calls for particular assessments. In addition, publicly available
literature on occurrence of TTX in marine bivalves and gastropods was considered. Collection and
appraisal of these occurrence data was carried out as described in Section 2.2.1 below.
2.1.2. Food consumption data
The EFSA Comprehensive European Food Consumption Database (Comprehensive Database)
provides a compilation of existing national information on food consumption at individual level. It was
ﬁrst built in 2010 (EFSA, 2011; Huybrechts et al., 2011; Merten et al., 2011). Details on how the
Comprehensive Database is used are published in the Guidance of EFSA (EFSA, 2011). The latest
version of the Comprehensive Database5 contains results from a total of 51 different dietary surveys
carried out from 1997 to 2012 in 23 different European Countries covering 94,532 individuals. A
summary table of the surveys included in the Comprehensive Database is presented in Annex A.
Within the dietary studies, subjects are classiﬁed in different age classes as described in Table 2;
two additional surveys provided information on speciﬁc population groups: ‘Pregnant women’ (Latvia)
and ‘Lactating women’ (Greece).
For acute exposure assessment, and considering the most recent dietary surveys, food
consumption data were available from 41 different dietary surveys carried out in 23 different European
countries. Overall, the food consumption data gathered by EFSA in the Comprehensive Database are
the most complete and detailed data currently available in the EU. Consumption data were collected
using single or repeated 24- or 48-h dietary recalls, as well as dietary records covering three to 7 days
per subject. Owing to the differences in the methods used for data collection, direct country-to-country
comparisons can be misleading.
2.1.3. Data on toxicokinetics and toxicity
The data were obtained as described in Section 2.2.2.
Table 2: Age classes considered in the EFSA Comprehensive European Food Consumption Database
Age class Age range
Number of
surveys
Number of
countries
Infants < 12 months old 6 6
Toddlers ≥ 12 months to < 36 months old 13 10
Other children ≥ 36 months to < 10 years old 24 17
Adolescents ≥ 10 years to < 18 years old 21 17
Adults ≥ 18 years to < 65 years old 29 21
Elderly ≥ 65 years to < 75 years old 18 15
Very elderly ≥ 75 years old 15 14
4 Regulation (EC) No 853/2004 of the European Parliament and of the Council of 29 April 2004 laying down speciﬁc hygiene
rules for the hygiene of foodstuffs. OJ L 139, 30.4.2004, p. 55–205.
5 http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb
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2.2. Methodologies
2.2.1. Collection and appraisal of EFSA occurrence data
The EFSA Evidence Management Unit (DATA Unit) initiated an ad-hoc collection of data to compile
occurrence data on TTX and TTX analogues in marine bivalves and gastropods. The European national
food authorities and similar bodies, research institutions and food business operators were invited to
submit data.
The data (n = 1,677 samples in total) for the present assessment were provided by national
authorities from Greece (n = 55), the Netherlands (n = 530) and the UK (n = 1,092). The data
submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample Description
for Food and Feed (EFSA, 2010a). The occurrence data were managed following EFSA standard
operational procedures (SOPs) on ‘Data collection and validation’ and on ‘Data analysis of food
consumption and occurrence data’.
A total of 1,677 samples of cockles, mussels, oysters, scallops, razor clams and other water mollusc
data on TTX and its analogues were available in the EFSA database. For all of them, analytical results
were provided to EFSA for tetrodotoxin (TTX), whereas only 1,135 analytical results were provided for
4-epiTTX, 1,080 for 5,6,11-trideoxyTTX, 1,080 for 11-norTTX-6-ol, 1,080 for mono-deoxyTTX, 1,135
for 4,9-anhydroTTX and 1,080 for 11-oxoTTX.
The UK reported analytical results for TTX, 4-epiTTX, 5,6,11-trideoxyTTX, 11-norTTX-6-ol, mono
deoxy TTX, 4,9-anhydroTTX and 11-oxoTTX. The LOD and LOQ were never reported for the
analogues. With the agreement of the data provider, the LOQ was determined as the minimum of
the reported positive values for 4-epi TTX, 5,6,11-trideoxyTTX, 11-norTTX-6-ol and 4,9-anhydroTTX. In
the case of 11-oxoTTX and mono-deoxyTTX, the highest LOQ identiﬁed among the other analogues
has been used. In all cases, the LOD was calculated by dividing the LOQ by 3.
The Netherlands submitted analytical results only for TTX. In addition information was reported on
the results of analyses of 4-epiTTX and 4,9-anhydroTTX. Solely TTX was found, except in one sample,
where 4-epi TTX was also detected.
Greece reported analytical results for TTX, 4-epi TTX and 4,9 anhydroTTX. In addition, the TTX
curve and assumption of equal molar response factor was used to estimate the levels of 5,6,
11-trideoxyTTX, 5-deoxyTTX, 11-deoxyTTX, 11-norTTX-6(R)-ol and 11-norTTX-6(S)-ol, but they were
either non-detects or non-quantiﬁed samples. Information on LOQ/LOD of these ﬁve analogues was
not reported and the data were not submitted to EFSA.
The reported LODs and LOQs are shown in Table 3 for TTX and all reported analogues. The
Panel noticed the difference in LODs/LOQs reported by different Member States, possibly related to
differences in the applied methods. This could have an inﬂuence on the exposure assessment, which is
for the average exposure mitigated by the fact that most of the concentration data came from the UK.
Table 3: Reported LODs and LOQs (in lg/kg fresh weight) for TTX and its analogues
TTX/TTX analogue
Country
United Kingdom(a) Netherlands Greece
LOQ LOD LOQ LOD LOQ LOD
TTX 1 0.5 10–25 3–5 7.2 2.2
11-norTTX-6-ol 6.4 2.13 – – n.r. n.r.
11-oxoTTX 6.4 2.13 – – – –
4,9-anhydroTTX 1.2 0.4 n.r. n.r. 21.1 6.2
4-epiTTX 0.12 0.04 10–25 3–5 7.6 2.3
5,6,11-trideoxyTTX 1.03 0.34 – – n.r. n.r.
mono-deoxyTTX 6.4 2.13 – – – –
5-deoxyTTX – – – – n.r. n.r.
11-deoxyTTX – – – – n.r. n.r.
LOD: limit of detection; LOQ: limit of quantiﬁcation; n.r.: not reported; – : not analysed; TTX: tetrodotoxin.
(a): In the case of analogues in samples from the UK, with the agreement of the Data Provider, LOQ = minimum of reported
values, LOD = LOQ/3. For 11-oxoTTX and mono-deoxyTTX, the highest LOQ/LOD identiﬁed among the other analogues has
been used as an assumption.
TTX in marine bivalves and gastropods
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2017;15(4):4752
In addition, the French Research Institute for Exploitation of the Sea (IFREMER) analysed in 2015,
90 samples of digestive glands from bivalves (67 mussels + 23 oysters) collected from several
sampling points along the French coast for TTX by liquid chromatography with tandem mass
spectroscopy (LC–MS/MS). After conﬁrmatory analysis of suspicious samples by liquid chromatography–
high-resolution mass spectrometry (LC–HRMS), all samples were below the LOD (33 lg/kg of digestive
glands, fresh weight). However, these data were not transmitted to EFSA and consequently could not
be included in the exposure assessment.
At a later stage in developing the opinion, an additional 57 samples were received for TTX in
mussels (n = 37) and oysters (n = 20) from the UK (Northern Ireland). The samples were taken
between May and September 2016 and all of them were non-detects, the LOD being 0.5 lg/kg. These
data were not included in the exposure assessment because they have been received too late.
Following the EFSA SOP on ‘Data analysis of food consumption and occurrence data’ to guarantee
an appropriate quality of the data used in the exposure assessment, the initial data set was carefully
evaluated applying several data cleaning and validation steps. Special attention was paid to different
data elements such as ‘Analytical method’, ‘Reporting unit’, ‘Expression of results’ and the codiﬁcation
of the different food samples under the FoodEx classiﬁcation.
The left-censored data (analytical data below the LOD/LOQ) were treated by the substitution
method as recommended in the ‘Principles and Methods for the Risk Assessment of Chemicals in Food’
(WHO/IPCS, 2009). The same method is indicated in the EFSA scientiﬁc report ‘Management of left-
censored data in dietary exposure assessment of chemical substances’ (EFSA, 2010b), as an option in
the treatment of left-censored data. The guidance suggests that the lower bound (LB) and upper
bound (UB) approach should be used for chemicals likely to be present in the food (e.g. naturally
occurring contaminants, nutrients and mycotoxins). At the LB, results below the LOQ or LOD were
replaced by zero; at the UB, the results below the LOD were replaced by the LOD and those below the
LOQ were replaced by the value reported as LOQ. Additionally, a middle bound (MB) approach was
used by assigning a value of LOD/2 or LOQ/2 to the left-censored data.
2.2.2. Collection and appraisal of publicly available toxicity, toxicokinetics and
occurrence data
No previous comprehensive risk assessments or reviews have been identiﬁed that could be used as
a starting point for the present opinion. Based on the short timeline given for the present mandate, it
was not possible to retrieve and scrutinise all potentially relevant literature without setting a time limit.
Based on a pilot search, it was decided to carry out an extensive literature search for publications from
the year 2000 onwards (because that would cover the most recent and up to date studies and also
reviews) and to combine it with the application of a ‘forward snowballing’ approach6 for retrieving
studies published before 2000 (see Jalil and Wohlin, 2012).
The extensive and comprehensive search for literature was conducted for peer-reviewed original
research, reviews and grey literature from the years 2000 until 11 August 2016. The search strategy
was designed to identify literature dealing with analytical determination, chemistry, formation,
metabolism and toxicity of TTX and also with its occurrence in bivalves and gastropods, effect of
processing and exposure to TTX. All search terms and Boolean operators used are presented in detail
in Appendix A. The literature search was not restricted to publications in the English language,
however, literature in other languages was only considered if an English abstract was available which
provided enough details to check the data. The literature search was performed on 11 August 2016 in
Web of Science7 which was identiﬁed as an appropriate and exhaustive database for retrieving
literature for the present evaluation.
The references resulting from the literature search were imported and saved using a software
package (EndNote8), which allows effective management of references and citations. Of the 6,766
retrieved citations duplicate references were removed using the EndNote software. The remaining
2,704 references were screened using title and abstract to identify the relevant literature.
Search categories ‘neurosciences or physiology’ were excluded upfront in the individual subsearches
(see Appendix A), as in the pilot search it was seen that papers in this category deal with the use of
TTX for investigating the mode and mechanism of action of the blocking of sodium channels and it
6 Identifying articles that have been cited in articles found in a search.
7 Web of Science (WoS), formally ISI Web of Knowledge, Thomson Reuters. http://thomsonreuters.com/thomson-reuters-web-
of-science/
8 EndNote X5, Thomson Reuters. http://endnote.com/
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was decided that such investigations are not of relevance for the present assessment. Upon screening
of the abstracts, all papers dealing with chemical features, methods of identiﬁcation and quantiﬁcation
of TTX and its analogues were considered as potentially relevant. Publications on the occurrence of
TTX and its analogues in species covered by the ToR (i.e. marine bivalves and gastropods) were
included, while information on occurrence in other species was excluded from further consideration.
Publications on determination of TTX and its analogues in species not covered by the ToR were not
considered as potentially relevant. Any papers on toxicokinetics and toxicodynamics, biomarkers and
detoxiﬁcation were included as possibly relevant. Publications on toxicity of TTX and its analogues
(such as acute, subacute, subchronic and chronic toxicity, genotoxicity, reproductive toxicity) in any
species were included as potentially relevant. Epidemiological studies, human exposure assessments
and reports on human poisoning cases were also included. Applying expert judgement, 411
publications were identiﬁed as potentially relevant for the present assessment.
During the development of the opinion, additional potentially relevant publications, not retrieved in
the above mentioned literature search (i.e. those published before the year 2000), have been
identiﬁed.
2.2.3. Methodology for exposure assessment
Based on food consumption data from the Comprehensive Database and the TTX occurrence data
described in Section 2.2.1, TTX acute exposure levels were estimated using a probabilistic approach.
Due to the relatively low levels of TTX analogues as compared to TTX and low estimated relative
potencies for the detected analogues, the CONTAM Panel decided not to carry out a speciﬁc exposure
assessment for each of the TTX analogues.
Acute exposure was assessed for each reporting day by multiplying the total consumption amount
for each food (each type of bivalve, e.g. oysters) by one occurrence level randomly drawn among the
individual results available for that type. Respective intakes of the foods consumed that day were then
summed and ﬁnally divided by the individual’s body weight. This process was iterated 1,000 times for
each reporting day. For the calculations, the UB approach was applied. The exposure was modelled
using SAS software.
In addition, acute exposure was also estimated by using the former 400 g portion and the 95th
percentile of actually observed contamination levels on TTX for the different species of water molluscs.
Marine gastropods could not be included in the exposure assessment as no occurrence and very
few consumption data were available on these species.
2.2.4. Methodology for risk assessment
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by WHO (2009), which include hazard identiﬁcation and characterisation, exposure
assessment and risk characterisation. In addition to the principles described by WHO (2009), EFSA
guidance documents were applied whenever appropriate.
3. Assessment
3.1. Methods of detection and quantiﬁcation
TTX acts via the blockage of voltage-gated sodium channels (Nav) leading to acute effects in
animals and humans (see Section 3.2.3 Mode of action). The initial test for the detection of TTX was
the mouse bioassay based on these acute effects after intraperitoneal (i.p.) injection. More recent
developments focussed on in vitro bioassays, immunochemical methods and chemical-analytical
methods.
3.1.1. Bioassays
3.1.1.1. Mouse bioassay
The mouse bioassay was the ﬁrst method developed and applied for the detection of TTX in
pufferﬁsh samples. The ﬁrst papers appeared in the 1950s (Hashimoto and Migita, 1951) and a
standardised method was proposed by McFarran (1966). This was adapted into an ofﬁcial method in
Japan (Sato and Kodama, 2015). The method is based on the injection of a sample extract i.p. in two
4-week-old male mice of a speciﬁc strain (ddY) with a bodyweight of 19–21 g as a ﬁrst step. If one of
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the mice dies, a third mouse is injected. The extract is prepared by mixing 10 g of sample with 25 mL
0.1% acetic acid followed by heating for 10 min. Subsequently, the extract is cooled, ﬁltered and the
ﬁltrate adjusted to 50 mL using 0.1% acetic acid. When the mice die within 30 min, the injected
extract contains TTX at or above 1 mouse unit (MU). It was shown that 1 MU of TTX corresponds to
0.22 lg TTX (Kawabata, 1978, referred to by Chen and Chou, 1998), corresponding to a dose level of
11 lg/kg bw (after i.p. injection).
It was established that relationship between the injected dose and the time to death very
reproducible and that hence the time of death gives a good indication of the injected dose. In
practice, a table is used describing the relationship between the dose and the mean time to death. In
case of a positive test response, dilution of the extracts may be needed to obtain a better estimation
of the concentration in the extract.
Several papers present curves expressing the relationship between the dose and the average time
to death of the mice for both TTX and saxitoxin (STX) (Konosu et al., 1968; Hashimoto and Noguchi,
1971). The curve for TTX is similar to that of STX, although a bit less steep. However, for STX, 1 MU
corresponds to a dose of 0.18 lg (EFSA, 2009d). Although male mice of the ddY strain are prescribed
within the Japanese protocol, Suzuki (2016) showed that ICR mice are equally sensitive, whereas e.g.
male mice of the BALB/c, C3H/He, C57BL/6 and DBA/2 strains are less sensitive. In practice, this could
result in a slight (25%) underestimation of the dose (shown to be 25% around an injected dose of
2 MU). This study shows the high reproducibility of the assay, at least with a pure standard. The
mouse bioassay in practice also detects TTX analogues, although most of these show a relatively low
response except for 11-oxoTTX (Yotsu-Yamashita and Mebs, 2003). The i.p. LD99 for mice for puriﬁed
11-oxoTTX in that study was estimated to be 16 lg/kg, so quite similar to the LD100 of 12 lg/kg bw
for TTX (see Section 3.2.4 on relative potencies).
In practice, the test conditions for TTX and STX are very similar, with the exception that acetic acid
rather than hydrochloric acid is applied for extraction of TTX. Furthermore, according to the speciﬁc
protocols, an equivalent of 0.2 g ﬁsh is injected for TTX and 0.5 g shellﬁsh for STX according to
version 1 of the SOP (EURL-MB, 2014). The latter implies that shellﬁsh samples with TTX levels higher
than 440 lg/kg (1 MU or 0.22 lg per 0.5 g), might have caused a positive response in the mouse
bioassay for STXs. The follow-up of false positive results in the MBA actually led to the discovery of
TTX in shellﬁsh in Greece (Vlamis et al., 2015), with levels up to 203 lg/kg digestive gland. These
levels are lower than the 440 lg/kg described above. However, it was shown that a concentration of
100 lg/kg, added to the digestive gland of non-contaminated mussels, caused the death of four out of
six mice with a median time to death of 310 min (range 240 min–24 h). So, it can be concluded that
the use of the MBA for routine testing of STXs, could have resulted in positive test results for shellﬁsh
samples containing TTX at levels above 440 lg/kg, but potentially even at levels as low as 100 lg/kg,
although effects occur after a longer period than the standard 60 min that should be applied for STXs
according to the protocols in the EU.
3.1.1.2. Cell-based assays
Since the mode of action of TTX is similar to STX, all cell-based assays for STX (EFSA CONTAM
Panel, 2009) will also detect TTX. Kogure et al. (1988) showed that neuroblastoma Neuro-2a cells can
be used for detection of TTX. Cells are treated with ouabain/veratridine (O/V) which will decrease cell
viability by increasing the intracellular sodium levels, but TTX (sodium channel blocker) will revert the
response, i.e. increase the viability. Initially, this was scored by counting the number of cells. However,
the use of a water soluble tetrazolium salt to check the viability, allows a much easier application of
the assay (Hamasaki et al., 1996). The test could detect 0.1 ng/well, which should be sufﬁcient to be
applied in practice. Although the assay was used for potential TTX-production by bacteria and
sediments, it is unclear whether it has been used for screening of ﬁsh or shellﬁsh samples.
3.1.1.3. Immunoassays/SPR techniques
Methods based on antibodies in either competitive inhibition enzymatic immunoassay (ELISA,
Raybould et al., 1992; Neagu et al., 2006; Stokes et al., 2012) or surface plasmon resonance biosensor
(SPR) (Yakes et al., 2011; Campbell et al., 2013) are potentially useful for qualitative identiﬁcation.
Especially useful are those using antibodies, since they also provide high throughput screening.
Nevertheless, at this time, these methods are not suitable for routine screening due to the lack of
cross reactivity for all TTX analogues, and as such may not identify all the analogues of TTX. Although
originally intended for STX, a radioreceptor assay that uses tritiated TTX allows the detection and
quantiﬁcation of TTX using synaptosomal membrane fractions (Doucette et al., 2000).
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3.1.2. Chemical-analytical methods
TTX can be identiﬁed and quantiﬁed by several analytical methods, such as gas chromatography-
mass spectroscopy (GC–MS), nuclear magnetic resonance (NMR), liquid chromatography with
ﬂuorescence detection (LC-FL) and LC-MS. The ﬁrst analysis of TTX was done by GC–MS (Naritia et al.,
1981) by conversion of TTX to the C9 base structure and later conversion to a trimethylsilane
derivative. GC–MS is not suitable for quantitation since TTX is non-volatile (Alcaraz et al., 1999; Bane
et al., 2014). NMR requires close to pure TTX samples to avoid the interference of matrix components.
LC-FL (Yasumoto and Michishita, 1985) is useful to simply detect TTX and major TTX analogues (11-
oxoTTX, 4-epiTTX and 4,9-anhydroTTX). However, it has the complication of the different ﬂuorescence
of other analogues (6-epi TTX is 20-fold more ﬂuorescent than TTX, and 11-deoxy TTX is 100-fold less
ﬂuorescent than TTX (Yotsu et al., 1989; Pires et al., 2005). Although the simultaneous analysis of STX
and analogues (paralytic shellﬁsh poisoning (PSP) group) and TTX has been reported by one single
LC-FL method (Rey et al., 2016), the differences in ﬂuorescence between PSP and TTX is still a
problem to solve.
This leaves LC–MS as the method of choice for the detection and quantiﬁcation of TTX and
analogues (see Table 4). LC–MS methods in general apply atmospheric pressured ionisation (API) with
an electrospray-ionisation (ESI) interface that operates in positive ionisation mode (Shoji et al., 2001;
Nakagawa et al., 2006; Tsai et al., 2006; Jen et al., 2008; Rodrıguez et al., 2012). The separation is
usually done with reverse-phase columns and solvents that contain an ion pair reagent, such as
ammonium heptaﬂuorobutyrate. Because TTX is a rather polar molecule, separation with reverse phase
is poor and a lower noise and better elution and sensitivity is obtained with hydrophilic interaction
liquid chromatography (HILIC, Nakagawa et al., 2006; Diener et al., 2007; Gerssen et al., 2011; Kudo
et al., 2012; Yotsu-Yamashita et al., 2013). In HILIC, a gradient with initially low aqueous/high polar
organic solvents is used, and not ion pair reagents, and a ﬁnal higher water proportion to elute polar
analytes. The typical positive ionisation provides a TTX ion of 320 (m/z) (McNabb et al., 2010).
Although the main product ion for TTX is 162 (m/z), other TTX analogues can generate this same ion,
and hence the MRM mode is commonly used to identify different analogues (Shoji et al., 2001; Jang
et al., 2010; McNabb et al., 2010, 2014; Yotsu-Yamashita et al., 2011, 2013).
To avoid the problem of the lack of calibrants for the various TTX analogues, the alkaline hydrolysis
(1N NaOH, 100°C, 45 min) of the compounds has been proposed, generating the C9 base 2-amino-6-
(hydroxymethyl)quinazolin-8-ol, that is common to all, and then use this structure for indirect
quantiﬁcation (McNabb et al., 2014). Although this allows the estimation of total TTX and analogues, it
does not account for toxicity and quantitation of each analogue. A conﬁrmatory analysis is required to
compare the proﬁles before and after hydrolysis (Turner et al., 2015).
Since 2012, there are certiﬁed standards available for TTX and 4,9-anhydroTTX but in general most
of the published studies have not used them. In Table 4, the different LC–MS methods for the analysis
of TTX and analogues are presented.
Table 4: Different LC–MS methods for the analysis of TTX and its analogues
Eluent Column(a),(b) m/z(c) LOD Matrix Reference
A: 10 mM ammonium formate and
10 mM formic acid in water
B: 80% acetonitrile and 20%
water with 5 mM ammonium
formate and 2 mM formic acid
ZIC-HILIC (5 lm,
150 x 2.1 mm)
272/162, 302/162, 304/162,
320/162
0.3 pmol Pufferﬁsh Diener et al.
(2007)
1 vol% acetonitrile, 20 mM
ammonium heptaﬂuorobutyrate,
10 mM ammonium formate (pH
4.0)
Reversed phase
(250 x 4.6 mm)
320/162, 304/176 0.7 pmol Pufferﬁsh Shoji et al.
(2001)
10 mmol/L ammonium formate
with formic acid (95:5, v/v), with
5 mM heptaﬂuorobutyric acid and
2% acetonitrile
Reverse phase
(5 lm, 2.1 x 15 mm)
320.1/162, 320.1/302.3,
320.1/256.2
0.13 ng/mL Human urine
and plasma
Fong et al.
(2011)
90% (v/v) 20 mM ammonium
acetate and 10% acetonitrile
Reverse phase
(150 x 4.6 mm)
320.1 0.5 ng/mL Mouse serum Hayashida et al.
(2004)
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Table 5. provides an overview of advantages and disadvantages of available methods.
Eluent Column(a),(b) m/z(c) LOD Matrix Reference
20 mM ammonium acetate–
methanol (75:25)
Reverse phase
(150 x 4.6 mm)
320.1/302, 320/284 0.1 lg/g Pufferﬁsh Horie et al.
(2002)
16 mM ammonium formate buffer
(pH 5.5) and acetonitrile (3:7, v/v)
HILIC (5 lm,
150 x 2 mm)
320/162, 302/162, 304/162,
288/224, 272/162
0.5 nmol/g Pufferﬁsh Jang et al.
(2010)
A: 0.1% formic acid in water
B: methanol
HILIC (150 x 4.6 mm) 320/302, 320/256, 320/162 1 ng/mL
(LOQ)
Blood serum Jen et al.
(2008)
A: 5% acetonitrile
B: 95% ACN with 1% acetic acid
(pH 3.5)
HILIC (1.7 lm,
100 x 2.1 mm)
319.92/161.80 319.92/
302.00
7.3 mg/kg Gastropod Nzoughet et al.
(2013)
A: 10 mM ammonium formate and
10 mM formic acid in water
B: 95% acetonitrile and 5% water
with 5 mM ammonium formate
and 2 mM formic acid
HILIC (3.5 lm,
150 x 2.1 mm)
320/302/162, 302/256/162,
304 /286/176, 290/272/162,
272/254/162
16 ng/mL Pufferﬁsh Rodrıguez et al.
(2012)
16 mM ammonium formate buffer
(pH 5.5)/acetonitrile
(3:7, v/v)
HILIC (5 lm,
150 x 2 mm)
320/162, 302/162, 290/162,
272/162 or high resolution
molecular weights 320.1088,
302.0983, 336.1038
0.6 pmol Pufferﬁsh Yotsu-Yamashita
et al. (2011),
Nakagawa et al.
(2006), Yotsu-
Yamashita et al.
(2013), Puilingi
et al. (2015)
(a): ZIC: Zwitterionic hydrophilic interaction chromatography.
(b): HILIC: Hydrophilic interaction liquid chromatography.
(c): m/z: 320 (TTX, 4-epiTTX, 6-epiTTX), 306 (11-norTTX-6,6-diol), 304 (11-deoxyTTX), 302 (4,9-anhydroTTX, 6-epi-4,9-anhydroTTX), 290 (11-norTTX-6
(S)-ol, 11-norTTX-6(R)-ol), 272 (5,6,11-trideoxyTTX). See Shoji et al. (2001).
Table 5: Overview of the advantages and disadvantages of available methods
Method Advantages Disadvantages
Mouse bioassay 1) Estimates combined effect
2) Allows (semi) quantiﬁcation,
similar to STX
1) Requires the use of animals
2) Does not discriminate between TTX and
STX
3) Does not provide information on the
toxin proﬁle
4) Not interlaboratory validated
Cell-based assays
methods
1) Estimate combined effect as they
use the mechanism of action of
the toxin group
2) Allow high-throughput screening
1) Do not provide information of the toxin
proﬁle.
2) Do not discriminate STXs from TTXs
3) Not interlaboratory validated
Antibody-based
methods (SPR,
ELISA)
1) Allow estimation of the
concentration within antibody
cross reactivity
2) Allow high-throughput screening
1) Do not provide information of the toxin
proﬁle
2) Not interlaboratory validated
3) Do not estimate overall toxicity
4) Due to point 3, may overestimate
largely the amount of equivalent TTX if
high amounts of low active compounds
are present and detected
5) Only detect the presence of the toxins
that the antibody cross-reactivity
allows
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3.1.2.1. Concluding remarks on methods of detection and quantiﬁcation
The mouse bioassay (MBA) has been the most widely applied test for TTXs, although not within the
EU. It detects combined toxicity and cannot clearly discriminate between TTXs and STXs. Biochemical
methods based on cell lines or antibodies offer a potential alternative for the MBA. In particular, the
cell-based assays are able to detect the various analogues of TTX, based on their effects but
depending on their toxic potency. Similar to the MBA, they cannot discriminate between the different
TTX analogues and will also detect STX and its analogues. As such they can be used for screening to
show the absence of toxins (both TTX and STX in one assay), but LC–MS is required for identiﬁcation
of the speciﬁc toxins and analogues. However, bioassays may detect novel analogues and in
combination with LC–MS can be used for their identiﬁcation, using a bioassay directed identiﬁcation
approach. Immunoassays will be more speciﬁc towards TTX and may be less suitable for broad
detection of different analogues, depending on their cross-reactivity with such compounds. Prior to
their use in routine control, suitable clean-up methods should be developed for the relevant matrices
and these methods should subsequently be validated in interlaboratory trials.
For information on toxin proﬁle and quantiﬁcation the chemical-analytical methods, in particular
LC–MS/MS methods are the most suitable. Some of these methods allow the simultaneous detection of
TTXs and STXs. Although validated within laboratories, they require further validation in interlaboratory
trials.
3.2. Hazard identiﬁcation and characterisation
3.2.1. Toxicokinetics
The toxicokinetics of TTX in humans are not fully understood. TTX seems to be rapidly absorbed in
the human digestive tract, based on the short delay between ingestion and onset of the symptoms
(see Section 3.2.2).
Data from human poisoning cases showed that TTX can be detected in the urine after a few hours
and up to 7 days after ingestion of contaminated ﬁsh (Oda et al., 1989; Fukushima, 1991; Kawatsu
et al., 1999; O’Leary et al., 2004), with concentrations ranging from 0.4 to 650 ng/mL (Table 6). In
plasma/serum, concentrations of TTX fall rapidly and may be undetectable after 6–24 h (Oda et al.,
1989; Yamazaki and Shibuya, 1995; O’Leary et al., 2004; Fong et al., 2011). Reported concentrations
in human cases ranged from < 1 to 320 ng/mL plasma/serum, as shown in Table 6.
Method Advantages Disadvantages
Chemical-analytical
methods
1) Provide information on toxin
proﬁle
2) Allow quantiﬁcation of TTX and
each analogue
1) Do not provide information about
toxicity
2) Highly dependent on available TEF
3) Highly dependent on available
standards
4) Not interlaboratory validated
ELISA: enzyme-linked immunoabsorbent assay; SPR: surface plasmon resonance; STX: saxitoxin; TTX: tetrodotoxin; TEF: toxic
equivalency factor.
Table 6: TTX concentrations in urine and serum/plasma reported in human cases of food poisoning(a)
Location Patients
Detection
method
LOD
(ng/mL)
TTX in urine (ng/mL)
TTX in plasma or serum
(ng/mL)
Reference
Japan 1 GC–MS n.a. 281 on day 2
43 on day 3
16 on day 4
<LOD on day 5
36.3 on day 1 (3 h after
ingestion)
< LOD on days 2, 3, 4, 5
Oda et al. (1989)
Japan 11 GC–MS 0.5 27.2–650 2.5–320 Fukushima (1991)
Japan 1 n.a. n.a. n.a. 52.3 on day 1
< LOD on days 3, 6, 9, 42
Yamazaki and
Shibuya (1995)
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No data are available regarding the distribution and the metabolism of TTX or TTX analogues in
humans.
No studies were identiﬁed on the toxicokinetics of TTX or analogues in animals, using for instance
radiolabelled compounds. However, from acute toxicity studies in mice (see Section 3.2.2, Toxicity), it
can be seen that LD50 values after i.p. application are between 25 to 50 times higher than after oral
administration.
TTX blood levels in treated female mice 2 h after a single administration by gavage were
6.46 + 1.91 ng/mL at 500 lg/kg bw, 1.29 + 0.18 ng/mL at 250 lg/kg bw and < LOQ at 125 lg/kg
bw. Data were obtained by ultra performance liquid chromatography–tandem mass spectrometry
(UPLC–MS/MS). TTX was quantiﬁed against a certiﬁed reference standard and the LOD was 0.5 ng/mL
Location Patients
Detection
method
LOD
(ng/mL)
TTX in urine (ng/mL)
TTX in plasma or serum
(ng/mL)
Reference
Japan 6 (a–f) n.a. 2 a) 86 (day n.a.)
b) 96 on 1st day n.a., 6 on
day 6 after 1st day
c) 82 on 1st day n.a., 17 on
day 5 after 1st day
d) 8 on 1st day n.a., 6 on
day 3 after 1st day
e) 102 on day n.a.
f) 74 on 1st day n.a., 13 on
day 5 after 1st day, 6 on
day 6 after 1st day, 7 on
day 7 after 1st day
n.a. Kawatsu et al.
(1999)
Australia 7 LC-FL 5 28–258 (24 h after ingestion) < LOD to 5 on day 1 O’Leary et al. (2004)
Taiwan 4 LC–MS 1.0 169–325 (15 h after
ingestion)
< LOD to 8 (15 h after
ingestion)
Hwang et al. (2005)
Japan 7 LC–MS/MS 0.1 15–150 0.9–1.8 Akaki and Hatano
(2006)
Taiwan 4 LC–MS 4.9
(15.6 nM)
15–109.7 (47–344 nM, 10 h
after ingestion)
< LOD to 13 (4.5–40.6 nM,
10 h after ingestion)
Tsai et al. (2006)
Taiwan 1 LC–MS/MS 0.1 n.a. 3.3 (12 h after ingestion) Jen et al. (2008)
Spain 1 LC–MS n.a. 285.38 (32 h after ingestion) 24.54 (32 h after ingestion) Fernandez-Ortega
et al. (2010)
LC–MS/MS n.a 211.1 for TTX
692.1 for 5,6,11-trideoxyTTX
(32 h after ingestion)
26.4 for TTX
86.5 for 5,6,11-trideoxyTTX
(32 h after ingestion)
Rodriguez et al.
(2008)
Hong-Kong 8 LC–MS/MS 0.13 59.3 (8 h after ingestion) < 2.5 (8 h after ingestion) Fong et al. (2011)
76.8 (8 h after ingestion) < 2.5 (8.25 h after
ingestion)
109.6 (8 h after ingestion) < 2.5 (7.75 h after
ingestion)
460.5 (6.5 h after ingestion)
351.9 (12.5 h after ingestion)
< 2.5 (6.5 h and 12.5 h
after ingestion)
44.8 (6.45 h after ingestion)
17.6 (12.5 h after ingestion)
< 2.5 (6.45 h and 12.5 h
after ingestion)
30.7 (8 h after ingestion) < 2.5 (8 h after ingestion)
48.2 (9 h after ingestion) < 2.5 (9 h after ingestion)
88.2 (5.5 h after ingestion) na
Korea 3 LC–MS/MS 0.32 3.9, 12.8, 29.7 (within 24 h
after ingestion)
Cho et al. (2012)
Bangladesh 38 ELISA 1.6 0.4–75.4 < 1.6 to 13.7 Islam et al. (2011)
ELISA: enzyme-linked immunosorbent assay; GC–MS: gas chromatography–mass spectrometry; LC–MS: liquid chromatography–mass spectrometry; LC–MS/MS:
liquid chromatography–tandem mass spectrometry; LC-FL: liquid chromatography-ﬂuorescence; LOD: limit of detection; LOQ: n.a.: time to intake TTX not available.
(a): Modiﬁed from Leung et al. (2011).
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and the LOQ was 1 ng/mL (Abal et al., 2017). More details on the study are presented in
Section 3.2.2, Toxicity.
In conclusion, little is known on the absorption and excretion of TTX and its TTX and no
information has been found on its distribution and metabolism.
3.2.2. Toxicity
No subchronic or chronic studies on TTX and its analogues have been identiﬁed.
3.2.2.1. Acute toxicity
Animal toxicity
Acute toxicity of TTX
According to Zimmer (2010) the overt clinical effects in experimental animals due to sublethal
doses of TTX result in severe impairment of neurological/neuromuscular functions under the control of
Na+ channels and results in urination, hypersalivation, retching, diarrhoea, diminution or the absence
of reﬂex, skeletal muscle fasciculations, lethargy, ataxia, ascending progressive paralysis, respiratory
pattern changes and dyspnoea. Death occurs upon blockade of the phrenic nerve, the diaphragm and
neurons in the central respiratory network. A direct effect of the toxin on the cardiovascular system
has been excluded, following extensive review of results obtained in several animal models (rat, rabbit,
dog and cat) considering TTX doses ranging from 2.5 to 80 lg/kg bw intravenously (i.v.) and 1 to
15 lg/kg bw i.p. (Zimmer, 2010).
Acute LD50 values for TTX have been established in different animal species exposed to the toxin
through different routes of exposure (see Table 7). In mice, an LD50 of about 10 lg/kg bw has been
observed after i.p. administration of TTX (see also Section 3.1.1 on bioassays).
An oral LD50 was determined in Swiss female mice (18–21 g) with an optimised 4-Level Up and
Down Procedure (according to OECD, 2008), using a certiﬁed standard of the toxin (Abal et al., 2017).
The methodology employed consisted of administration of a saline solution of TTX (98% pure,
personal communication Paula Abal) by gavage as a single oral dose (10 mL/kg) to Swiss female mice
at doses of 25, 75, 125, 250, 500 and 1,000 lg/kg bw. Based on the outcome, the number of mice
treated was decreased/increased with each level (animal number being 3, 5, 7 and 9 at the ﬁrst,
second, third and fourth level, respectively). Also, the dose varied depending on the results obtained in
the previous level (starting dose 1,000 lg/kg bw, dose decreased at the next level if more than 50%
of the mice died, increased if less than 50% of the mice died within the study duration of 2 h). In
practice, every next dose had to be decreased, until a dose of 125 lg/kg bw, with no dead animals
within 2 h among the nine treated ones. No dead animals were observed within 2 h with two
additional dose levels of 25 and 75 lg/kg bw. Symptoms after exposure to the toxin and time to death
were registered (e.g. numbness, apathy, piloerection, paralysis of extremities, seizures). The number
of dead animals increased from 0% (0/9) at 125 lg/kg bw to 57% (4/9), 80% (4/5) and 100% (3/3)
at the dose levels of 250, 500 and 1,000 lg/kg bw, respectively. Based on this, the estimated LD50 for
TTX was 232 lg/kg bw, the LD100 was 1,000 lg/kg bw. This conﬁrms the steep dose–response curved
observed after i.p. treatment of mice (Kao and Fuhrman, 1963).
First signs of poisoning (apathy in all treated animals and piloerection in two out of nine treated
mice) occurred at a lowest dose of 125 lg/kg bw, while no behavioural signs were observed at the
dose of 75 lg/kg bw (n = 9). At doses of 250 lg/kg bw and higher paralysis of extremities, seizures
and death were observed. Macroscopic organ examination showed dilated stomachs with liquid and
gas accumulation for doses of 125 lg/kg bw and higher and cardiac stiffness at 1,000 lg/kg bw.
Another study reported the acute toxicity of TTX in mice after various routes of application (Xu
et al., 2003). For mice, this included intragastric application, showing a 50-fold lower toxicity than after
i.p. or subcutaneous application. Also rabbits were tested, however, the results reported were unclear
and are therefore not reported in Table 7 below.
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Acute studies with pharmacological TTX preparations
To study the effects of TTX on pain reduction, Marcil et al. (2006) injected rats and mice with
sublethal doses of TTX (a sterile, non-pyrogenic aqueous solution for parental administration
containing TTX 15 lg/mL, 99.8% pure). Male Wistar rats (170–220 g) and male Swiss Weber mice
(20–30 g) were treated subcutaneously (s.c.) with TTX at doses of 0.3, 1, 3 or 6 lg/kg bw (dilution in
saline 0.9%) 30 min before pain induction. TTX adverse effects were monitored and recorded up to
90 min, the time needed to complete the longest battery of pain tests. No respiratory distress, motor
impairment or paralysis was evident but treated animals displayed antinociceptive9 effects. The ED50
was between 0.62 and 3 lg/kg bw depending on the pain model, showing no respiratory distress,
motor impairment or paralysis.
Guzman et al. (2007) injected mice with a solution of TTX (15 lg/mL, 99.8% pure). Male (26–34 g)
and female (21–25 g) CD-1 mice were administered s.c. with TTX at doses of 2, 4 and 8 lg/kg bw and
sacriﬁced 24 h (all doses) and 48 h (TTX 8 lg/kg bw) later for bone marrow dissection. No mortality
and no clinical signs were evident in mice receiving 2 lg TTX per kg bw. Piloerection, ataxia, hunched
back, dyspnoea, decreased motor activity, muscular weakness and palpebral ptosis were observed at
8 lg/kg bw in mice. Less severe dyspnoea and decreased motor activity was evident at 4 lg/kg bw.
Authors did not specify the time of occurrence of behavioural effects. It is thus inferred that TTX
adverse effects occur along the timeframe before sacriﬁce. Also, male Sprague–Dawley rats
(169–195 g) were injected s.c. twice (second dose given 14 h after the ﬁrst and 2 h prior to sacriﬁce)
with TTX at doses of 2.4 and 8 lg/kg bw. Rats were underactive and displayed nervous behaviour,
irregular and fast respiration, ﬂattened posture, unsteady gait and partially closed eyelids before
sacriﬁce occurring 16 h after TTX administration. Reduced body tone was also evident in high dose
animals (8 lg/kg bw).
In Marcil et al. (2006), sublethal doses of TTX (single administration, 0.3–6 lg/kg of a 99.8% pure
solution) administered s.c. to rats and mice were not associated with the occurrence of clinical signs
within 30–90 min. On the contrary, clinical signs were evident in a dose-dependent manner in mice
exposed to TTX (single administration, 2–8 lg/kg bw of a 99.8% pure solution), but observed in a
2–48 h time frame (Guzman et al., 2007). In this study, no effects were evident at 2 lg/kg (Guzman
et al., 2007).
Acute toxicity studies with TTX from extracts and pufferﬁsh meat
Some studies describe the toxicity induced by i.p. injection of extract, homogenate (Zaki et al.,
2001; Saoudi et al., 2011) or oral administration (Saoudi et al., 2009) of meat obtained from different
Table 7: Summary of acute toxicity studies with laboratory animals
Species
Route of administration/
Purity of compound
LD50 (lg/kg bw) References
Mouse Intraperitoneal
TTX source unknown
10.7 Xu et al. (2003)
Mouse Intraperitoneal(a)
Purity: 99.8%
9 (8.2–9.8) Marcil et al. (2006)
Mouse Intraperitoneal
Purity not reported
10 Kao and Fuhrman (1963)
Mouse Subcutaneous
Purity not reported
12.5 Xu et al. (2003)
Mouse Subcutaneous
Purity not reported
10 Kao (1966)
Mouse Intragastric
Purity not reported
532 Xu et al. (2003)
Mouse Oral (gavage)
Purity: 98%
232 Abal et al. (2017)
Rat Intramuscular(a)
Purity: 99.8%
11.1 (10.5–11.7) Marcil et al. (2006)
bw: body weight; TTX: tetrodotoxin.
(a): No experimental data provided.
9 Reducing sensitivity to painful stimuli.
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types of pufferﬁsh (Lagocephalus sceleratus and Lagocephalus lagocephalus) as a source of TTX.
Reversible increase in different neurotransmitters (serotonin, acetylcholine, histamine and
noradrenaline) (Zaki et al., 2001), decrease of serum enzyme activity (i.e. aldolase (ALS), alanine
aminotransferase (ALT), alkaline phosphatase (ALP), y-glutamyl transpeptidase (GTP) and lactate
dehydrogenase (LDH)), hepatic damage (increased lipid peroxidation, focal necrosis, hepatic chord,
inﬁltration of lymphocytes, congestion in central veins and sinusoids; Saoudi et al., 2009, 2011) were
observed. No information on the amount of TTX or the presence of analogues was provided.
3.2.2.2. Concluding remarks on acute toxicity
The acute LD50 values for TTX in mice range from 8.2 to 10.7 lg/kg bw following i.p. exposure.
Similar values, 10–12.5 lg/kg bw were reported upon s.c. administration. LD50 levels in mice increased
to 232 and 532 lg/kg bw after oral administration.
A NOAEL of 75 lg/kg bw (respective LOAEL was 125 lg/kg at which apathy was observed in 9/9
animals) was established by the authors in an acute oral study in mice with a single administration
(Abal et al., 2017). In this study, at higher doses lethality was observed, i.e. at doses of 250 lg/kg bw
(four out of seven animals or 57%), 500 lg/kg bw (four out of ﬁve animals or 80%) and 1,000 lg/kg
bw (three out of three animals or 100%). The CONTAM Panel noticed the relatively short duration of
the observation period (2 h) after which all surviving animals were killed. This precluded the
observation of potential deaths and other effects occurring at later time-points, as observed by Vlamis
et al. (2015) with shellﬁsh extracts spiked with TTX at relatively low levels.
3.2.2.3. Genotoxicity studies
TTX did not show any genotoxic activity in a battery of good laboratory practice (GLP)-compliant
in vitro and in vivo assays conducted by Guzman et al. (2007) according to OECD guidelines, and
including an Ames test (bacterial reverse-mutation assay), an in vitro human lymphocyte chromosome-
aberration assay, an in vivo mouse bone-marrow micronucleus assay and an in vivo rat-liver
unscheduled DNA synthesis (UDS) assay. The TTX used in this study was commercially obtained. For
in vitro assays, TTX powder (purity of 97.1%) was dissolved in a 0.02% acetic acid solution. For
in vivo assays the pharmaceutical dosage form ‘Tetrodotoxin Injectable’ was used (purity of 99.8%).
Maximum test concentrations in in vitro assays were determined by the TTX limit of solubility in the
formulation vehicle. In the Ames test, TTX was tested at concentrations of up to 200 lg/plate in four
Salmonella Typhimurium histidine auxotrophic strains (TA98, TA100, TA1535 and TA1537) and an
Escherichia coli tryptophan-requiring strain (WP2 uvrA pKM101).
In the chromosome-aberration assay, human lymphocytes were exposed to TTX at concentrations
of up to 50 lg/mL for 3 and 20 h in the absence of S9, and for 3 h in the presence of S9.
For the in vivo assays, maximum tested dose levels were determined by the acute lethal toxicity of
TTX after s.c. injection. Positive control animals were dosed orally (gavage). In the mouse
micronucleus assay, TTX dose levels of 2, 4 and 8 lg/kg bw (in 0.02% acetic acid) were administered
by s.c. injection to groups of ﬁve male and female CD-1 mice, and bone-marrow samples from femurs
were taken 24 and 48 h (high-dose animals only) after administration.
In the UDS assay, male Sprague–Dawley rats were given TTX by s.c. injection (in 0.004% acetic
acid) on two occasions with a 14-h interval at dose levels of 2.4 and 8 lg/kg bw, the last dose being
administered 2 h before liver perfusion and hepatocyte culturing. Relevant vehicle and positive control
cultures and animals were included in all assays.
Crude extracts from skin and liver of the porcupineﬁsh (Diodon hystrix) containing TTX (0.5 mg/mL),
caused spindle ﬁbre aberration in the human lymphocyte chromosome aberration assay, but this was
not the case with extracts from intestine, eyes and gonads. All the ﬁve extracts showed lack of DNA
damage in the comet assay (Lokesh et al., 2016).
A quantitative structure–activity relationship (QSAR) analysis was conducted using DEREK, VEGA
and the Danish (Q)SAR data base, to obtain information on the potential properties and activities of
4,9-anhydroTTX and 11-oxoTTX. No structural alert for genotoxicity was identiﬁed for either analogue
(data available from EFSA on request).
3.2.2.4. Human observations
TTX is a potent neurotoxin, inhibiting nerve and muscle conduction by blocking sodium channels.
Symptoms of toxicity can occur within 10–45 min of ingestion, although a delayed response of 3–6 h
has also been reported (Hwang and Noguchi, 2007). Bane et al. (2014) and Lago et al. (2015)
described four grades of TTX poisoning (both citing Fukuda and Tani, 1941):
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Grade 1: perioral numbness and paraesthesia, with or without gastrointestinal symptoms;
(nausea, vomiting, diarrhoea, and abdominal pain);
Grade 2: lingual numbness (of face and other areas), early motor paralysis and incoordination,
slurred speech with normal reﬂexes;
Grade 3: generalised ﬂaccid paralysis, respiratory failure, aphonia and ﬁxed/dilated pupils;
Grade 4: severe respiratory failure and hypoxia, hypotension, bradycardia, cardiac dysrhythmias
and unconsciousness may occur.
In fatal cases, progressive paralysis leads to death by respiratory failure and cardiac collapse (Lago
et al., 2015). Liu et al. (2011) proposed that electrophysiological changes, such as nerve conduction
velocity and somatosensory-evoked nerve potentials could be used to determine the extent, course
and range of nerve system damage in patients with acute TTX poisoning, but did not associate the
severity of the changes to speciﬁc doses of TTX.
TTX poisoning has most frequently been reported in Japan, associated with consumption of
pufferﬁsh (fugu), which is considered a delicacy. Regulations were introduced in Japan in 1983 to
deﬁne species of pufferﬁsh that are allowed to be caught and marketed, and for careful preparation of
them, but there continue to be cases of pufferﬁsh poisoning (Noguchi and Ebesu, 2001; Noguchi
et al., 2011a,b). These authors reviewed data for pufferﬁsh poisoning incidents in Japan over the
period 1965–2010, including annual data for the period 1995-2010 with no clear trend over this latter
period.
Cases of TTX poisoning have also been reported in a number of other countries including Australia,
Bangladesh, Brazil, China, Israel, Morocco, Singapore, Spain, Taiwan and the USA, resulting from
consumption mainly of pufferﬁsh, but also from goby ﬁsh and marine gastropods.
The doses of TTX that cause symptoms of acute toxicity, or lethality, in humans are unclear. Values
for lethal doses are reported in the literature, either without attribution or by citing secondary
literature and reviews, and the CONTAM Panel was not able to trace the origins of these values, and
hence their inherent uncertainties and assumptions. Hwang et al. (2005), citing Tani (1945), noted
that the MLD10 of TTX for a human by oral administration is estimated to be 10,000 MU,
corresponding to 2 mg based on the observation that the minimum dose that kills a mouse (1 MU) is
equal to 0.2 lg of TTX. Noguchi and Ebesu (2001) and Noguchi et al. (2011a,b) mention the same
MLD for humans but without citing a source. Since 50 kg is commonly used as a default bodyweight in
the TTX scientiﬁc literature, presumably relating to Asian individuals, the amount of 2 mg is sometimes
extrapolated to 40 lg/kg bw for these values. The Hazardous Substance Databank (HSDB)11 notes
that ‘a fatal dose may be as little as 1–4 mg per person’, citing a text book (Klaasen, 2001) as the
source, which in turn does not provide any information on the basis of this assertion. Some papers
also refer to a lowest dose resulting in symptoms of 0.2 mg (e.g. Tsang and Tang, 2007; Katikou
et al., 2009), which corresponds to 4 lg/kg bw for a 50-kg individual. Again the basis for this
observation was initially unclear as no references are provided in these papers. However, the CONTAM
Panel was able to identify two reviews describing intoxications at this level (Noguchi and Ebesu, 2001;
Hwang and Noguchi, 2007). If this value were robust, it could be regarded as a LOAEL for sensitive
individuals. However, there is a lack of information on the accuracy of the exposure estimate. This is
particularly problematic for case reports related to marine biotoxins, since there is uncertainty with
respect to the concentration of toxin in the food that was actually consumed. There is potential for the
reported exposures to be either under- or overestimated, and without information on the ways that
these estimates were derived, and the number of individual case reports reviewed, it is not possible to
characterise the degree of uncertainty.
Table C.1 in Appendix C summarises the reports of TTX poisoning retrieved in the literature
searches or identiﬁed from other sources for the same time period, that do not provide information on
possible consumption and therefore exposure cannot be estimated. The following paragraphs provide
detail on poisoning cases reported since 2000, for which TTX exposure has been estimated.
The review of Noguchi and Ebesu (2001) described a number of case reports, with limited detail,
including two that provided estimates of exposure. The primary reference cited by the authors is an
10 There is unclarity on the terminology, e.g. the review of Bane et al. (2014) transposed the MLD ‘minimum lethal dose’
reported by Noguchi and Ebesu (2001) and Noguchi et al. (2011a,b) into a ‘median lethal dose’. Similar inconsistencies are
seen throughout the literature. Given that a median lethal dose is a statistical outcome of an acute toxicity study, it seems
likely that where a human MLD is referred to, it actually means a minimum lethal dose, however there is also uncertainty in
this assumption.
11 https://toxnet.nlm.nih.gov/newtoxnet/hsdb.htm, accessed 5 October 2016
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earlier publication in Japanese (Noguchi and Akaeda, 1998). A 48-year old male in Japan became ill
within 1 h of eating ‘more than 4 livers’ and some ﬂesh of wild puffer. He subsequently died despite
hospitalisation. The leftover liver contained 715–4,260 MU/g and it is stated that he ingested more
than 10,000 MU. Since, 10,000 MU would correspond to only 2–14 g liver, it is likely that he must have
consumed very much more than 10,000 MU and the mention of 10,000 is likely to be based on the
assumption that this is the MLD. The CONTAM Panel noted that this report does not provide good
information on the lethal dose. A second case describes a 59-year old female who cooked and
ingested 3.5 livers of wild pufferﬁsh (estimated weight 300 g). After 50 min, she developed numbness
in the lips and tip of the tongue, followed by numbness of the ﬁngers and vomiting, and then more
severe symptoms (dyspnoea, mydriasis and paralysis of the extremities) 5 h later in the hospital. She
recovered following artiﬁcial respiration. After 9 h, she developed arrhythmia for which she was
treated with drugs. The report states that the leftover liver contained 3.5 MU/g, and estimated that
the total amount of TTX ingested was 900–1,000 MU (equivalent to 0.18–0.2 mg TTX). The CONTAM
Panel noted that it is not clear what the ‘leftover liver’ was or if the concentration was actually
comparable to the livers she consumed.
A total of 36 individuals (18 men and 18 women) were admitted to hospital in Khulna, Bangladesh,
after consuming pufferﬁsh (Ahmed, 2006). Seven died as a result of respiratory failure, and the others
recovered following treatment. Six days after the incident, pufferﬁsh were collected from a ﬁsh-landing
centre adjacent to the implicated area, and stored frozen for transfer to a laboratory. The partially
thawed ﬁsh were then dissected into skin, muscle, liver gonad and viscera and TTX concentration was
estimated. Concentrations in the poisoning-related samples were 13.2–18.9 MU/g in the skin,
2.7–4.4 MU/g in the muscle, < 2.0–4.9 MU/g in the liver, < 2.0–132 MU/g in the gonads and
14.8–37 MU/g in the viscera (excluding liver). The victims ate the whole ﬁsh including the gonads, but
excluding the viscera. The authors reported the average toxicity in the whole body without the viscera as
about 17 MU/g, and estimated that the lowest amount of ﬁsh consumed by one of the fatalities was
about 150 g, which would be equivalent to 2,550 MU. Since 10,000 MU corresponds to approximately
2.2 mg TTX, the ingested amount would be about 0.56 mg, which corresponds to 11 lg/kg bw for a 50-
kg person. However, the CONTAM Panel noted that this estimate is subject to considerable uncertainty
resulting from the time between the outbreak and sampling of ﬁsh (6 days after the incident), the use of
the average concentration and assumption on lowest amount consumed by the fatal cases.
Hwang and Noguchi (2007) reported a case of TTX poisoning that occurred in Taiwan in 1998. A
52-year old woman with uraemia and her healthy 55-year-old husband ate ﬁsh soup. About 4 h later,
the woman developed a headache, lingual and oral tingling and numbness in the distal parts of all four
limbs. Her symptoms became increasingly severe leading to respiratory distress, cyanosis and
comatose-like state, from which she eventually recovered following hospital treatment. The husband
remained asymptomatic. The remains of the cooked ﬁsh were found to contain 25 MU/g and it was
estimated that both the man and the woman consumed about 0.2 mg TTX. The authors suggested
that there was a synergistic effect of uraemia and TTX (Hwang and Noguchi, 2007).
Frozen ﬁsh purchased from an Asian market in Chicago was consumed in soup by a family of three.
(Cohen et al., 2009). The woman (47-year-old) suffered symptoms of TTX poisoning within 30 min and
was admitted to hospital, where she recovered following treatment. The husband (55-year-old)
consumed less of the soup and experienced less severe symptoms, not requiring hospitalisation. The
10-year-old daughter tasted only one spoonful of the soup and did not experience any symptoms.
Three samples of left-over soup were analysed by LC–MS, and found to contain TTX at
4.63  1.67 lg/g TTX. STX was not detected. Based on the amount of soup consumed (700 and
230 mL, respectively) and the mean TTX concentration, it was estimated that the female patient
consumed ‘as much as 3 mg TTX’, and the husband consumed ‘as much as 1 mg TTX’. Based on a 70-kg
adult, these correspond to 42 and 14 lg/kg bw, respectively. Samples of similar ﬁsh, labelled as ‘frozen
ﬁsh’ were purchased from the same market and identiﬁed as pufferﬁsh of the genus Lagocephalus
(Cohen et al., 2009). The CONTAM Panel noted that in this case report, TTX was measured by chemical
analysis of samples of the ﬁsh soup that caused the TTX poisoning, and therefore, the exposure estimates
are likely to be more reliable than in outbreaks where the analysis is conducted on ﬁsh obtained from the
same region subsequent to that causing the poisoning.
The ﬁrst report of poisoning due to TTX in Europe is from Malaga, Spain. A 49-year-old man
consumed trumpet clam (Charonia lampas sualiae) that had been caught off the southern coast of
Portugal and sold in a local ﬁsh market (Rodriguez et al., 2008; Fernandez-Ortega et al., 2010;
Fernandez-Fıgares et al., 2013). He boiled it for 45 min, then ate the ventral portion and a few
minutes later started to feel perioral numbness, which extended to both arms, followed by abdominal
TTX in marine bivalves and gastropods
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2017;15(4):4752
pain, nausea and vomiting. His symptoms worsened and he was admitted to hospital for treatment. He
recovered and was discharged 72 h after admission. By MBA, the non-ingested shellﬁsh was found to
contain 1.51 and 255 mg/kg in the meat and digestive gland, respectively. The presence of TTX in the
digestive gland was conﬁrmed by LC–MS, and quantiﬁed at a level of 248.5 mg/kg. In the ﬂesh, TTX
could not be detected (LOD not presented). Analysis of TTX analogues was not reported in this paper.
The authors noted that ‘consumption of the digestive glands of the mollusc, about 5 g, was enough to
produce the symptoms described’ (Fernandez-Ortega et al., 2010). Consumption of about 5 g at the
TTX level of 248.5 mg/kg would lead to an exposure of 1.24 mg TTX or 18 lg/kg bw in a 70-kg adult
but from the publications it is unclear if the patient consumed part of the digestive gland. Rodriguez
et al. (2008) also reported on this case and stated that analysis of the digestive gland by LC–MS
showed that it contained 315 mg/kg of TTX and 1,004 mg/kg of 5,6,11-trideoxyTTX. Both were not
detected in the meat. This TTX analogue seems much less toxic than TTX (see Section 3.2.4 on
relative potencies of TTX analogues) although Rodriguez et al. (2008) assumed a higher relative
potency (about 0.13) in order to explain the discrepancy between the level of TTX detected with LC–
MS and the overall toxicity in the mouse bioassay. Taking into account that potency, the amount of 5 g
digestive gland would lead to an exposure of about 2 mg, being the often reported MLD for humans.
The CONTAM Panel noted that based on the three publications, there is considerable uncertainty on
the actual amount consumed and whether this was only the meat or also the digestive gland. Based
on the mouse bioassay, the amount of TTX that could have been ingested with the meat appears to
be much lower than if he would have consumed part of the digestive gland. However, based on
personal communication (Luis Botana), the patient reported to have ingested an undeﬁned part of the
digestive gland.
You et al. (2015) conducted a case series analysis of an outbreak of TTX poisoning associated with
consumption of goby ﬁsh in three towns of the Guangdong province of China in 2012. The number of
cases that were hospitalised was 22 (9 males, 13 females, aged 31–78 years), showing mild to severe
symptoms but no deaths. TTX was measured by LC–MS/MS in one sample of remaining cooked goby
from one of the cases, and in two samples of uncooked gobies from the same batch responsible for
the poisoning purchased from the same markets. The concentration was 2.09 mg/kg in the cooked
sample. In the two uncooked samples, the concentrations were 1.86 and 2.78 mg/kg in the muscle,
and 2.0 and 3.0 mg/kg in the viscera. Based on the amounts the patients reported they had
consumed (100–300 g), the authors estimated that they had ingested more than 0.63 mg of TTX,
which corresponds to more than 12.6 lg/kg bw for a 50-kg adult.
3.2.2.5. Concluding remarks on human observations
Overall, the human case reports indicate that poisoning can result from TTX exposures in the
region of 4–42 lg/kg bw and higher, but these values are subject to multiple limitations (e.g. not
deﬁned amounts of actual consumption, material analysed might not represent material that has
actually been consumed, concentration estimates of TTX might not be accurate due to a lack of
certiﬁed standards). Moreover, the CONTAM Panel was unable to identify the original data that
underlay the MLD of 2 mg that is reported by several authors in the literature. The Panel noted
inconsistencies in the use of the term MLD in human cases.
3.2.3. Mode of action
The targets of TTX are the voltage-gated sodium channels (Nav), which belong to a superfamily of
channels that also include potassium (Kv), calcium (Cav) and cyclic nucleotide-gated channels (Jan and
Jan, 1992). Nav channels are multimeric complexes containing a pore forming a-subunit and one or
more b-subunits, and show a high similarity with Cav (Strong et al., 1993). The crystal structure of the
channel has been resolved to understand the interaction of b- and a-subunits (Payandeh et al., 2011).
There are four known b-isoform subunits (b1– b4); b1 are associated to the nervous system, and b2
are associated to the skeletal muscle. b-subunits belong to the cell adhesion molecules (CAMs)
immunoglobulin superfamily (Patino and Isom, 2010). The coexpression with b-subunit is required for
the a-subunit to show native Nav functions. The pore of the channel is the transmembrane a-subunit
that contains four domains, each one with six transmembrane hydrophobic domains. Based on the
a-subunit, Nav are classiﬁed in nine isoform types (Nav 1.1.–1.9) that show different tissue presence
and pharmacological features. TTX is active on Nav 1.1, 1.2, 1.3, 1.4, 1.6 and 1.7 subtypes in the
nanomolar range (IC50 < 10 nM). Nav 1.6 is sensitive to 1 nM TTX (Wingerd et al., 2012). All other
channels (Nav 1.5, 1.8 and 1.9) show a low sensitivity to TTX being in the lM range. Nav 1.1, 1.2, 1.3,
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1.6 and 1.7 are abundant in the nervous system, and Nav 1.4 is common in the skeletal muscle
(Zimmer, 2010; Teramoto and Yotsu-Yamashita, 2015). The tissues involved in TTX symptoms include
respiratory system, involving blockade of the phrenic nerve, the diaphragm and neurons in the central
respiratory network, skeletal muscle and tissues from the digestive track (Zimmer, 2010).
The sensitivity of the various Nav channels to Na+ and to voltage resides on the a-subunit, and it is
this subunit being responsible for the initiation and propagation of the action potential in excitable cells
(Catterall, 1984; Hartshorne and Catterall, 1984; Alexander et al., 2013). Na+ currents are either TTX-
sensitive (TTX-s) or TTX-resistant (TTX-r) (Roy and Narahashi, 1992; Kiernan et al., 2003). TTX-s
currents contribute to action potential generation and to the control of peripheral nerve excitability
(Baker and Bostock, 1997). TTX-r currents characterise small neurons (Brock et al., 1998), many of
which are involved in nociception.
The mechanism of action of TTX consists of the extracellular blockade of the channel pore by
binding to site 1, hence inhibiting Na conductance (Narahashi, 1974; Hille, 1975). TTX, thus, has effects
both on action potential generation and on impulse conduction (Isbister and Kiernan, 2005). The result
is the blockade of the neuron action potential and muscle paralysis. This mechanism is shared by similar
water-soluble heterocyclic guanidinium alkaloids, including STX and analogues (Hartshorne et al., 1980;
Huang et al., 2012; Walker et al., 2012; FAO/WHO, 2016; Pratheepa and Vasconcelos, 2017). The
chemical structures of TTX and STX have certain similarities and dissimilarities. The molecular volumes
for both STX and TTX are similar (251 and 252 A3, respectively), despite their disparate molecular
shapes, TTX is a monovalent and STX is a divalent cation, which explains some differences in the
afﬁnities of TTX and STX for different Nav isoforms (Zhang et al., 2010; Walker et al., 2012; Pratheepa
and Vasconcelos, 2017). Walker et al. (2012) studied the afﬁnity of TTX and STX for NaV 1.7 and NaV
1.4 in CHO cells transfected with cDNA for human Nav1.7 or rat Nav1.4. STX blocked rNav1.4 with an
IC50 value of 2.8  0.1 nM compared to 17.1  1.2 nM for TTX. The IC50 values for hNav1.7 were
702  53 nM for STX and 18.6  1.0 nM for TTX. The human Nav1.7 possesses a 2-aa sequence
variation compared with all other Nav isoforms, which results in differences in the binding afﬁnity for
TTX and STX. Structurally related GTX-3 also displayed a signiﬁcant reduction in potency against
hNav1.7 compared with rNav1.4 (1,513  55 vs. 14.9  2.1 nM, respectively).
The interaction of the TTX molecule is based on the combined guanidinium group with the presence
of six hydroxyl groups, especially the C-11 OH (Choudhary et al., 2003). The different number of
hydroxyl groups is also responsible for the different potencies of TTX analogues (see Section 3.2.4
Relative potency of TTX analogues). The blockade of the sodium channel pore is explained by means
of a network of hydrogen-bonds between TTX and three acidic residues on the outer side of the
selectivity ﬁlter, with the guanidine group adopting a lateral orientation (Chen and Chung, 2014). TTX
blockade of Na+ channels is consistent with the signiﬁcant changes evident in Na+ channel dependent
nerve excitability parameters in humans upon intoxication (Kiernan et al., 2005).
Oda et al. (1989) carried out serial nerve conduction studies in a single patient and documented
reduced amplitudes of compound motor and sensory potentials, slowing of conduction velocities, and
lengthening of distal motor latencies and F-wave latencies. Neurophysiological investigations
incorporating nerve excitability studies were done in four patients with TTX poisoning within 24 h of
ingestion, and the results compared with previously established normative data (Isbister et al., 2002;
Kiernan et al., 2005). Nerves in these four patients were of high threshold, had slow conduction, and
had reduced amplitude compound potentials, suggesting some axons were unable to conduct. The
effect on amplitude was greater in sensory neurons than motor axons, consistent with the prominence
of sensory symptoms (dysaesthesia and numbness) over motor involvement (weakness) in the patients
(Isbister et al., 2002; Kiernan et al., 2005).
According to a review conducted by Zimmer (2010), TTX has no direct effect on the heart. The
transient or permanent reduction of the heart rate is most likely the result of a complex systemic
reaction to TTX intoxication. Pratheepa and Vasconcelos (2017) also reported that the sodium channels
in the cardiac muscles have less binding afﬁnity to the toxin, due to the presence of cysteine residue in
cardiac sodium channel at position 385 (Tyr385).
Based on the high selectivity of TTX for certain sodium channels, it is tested in pharmacological research
for example as a possible therapeutic agent for treatment of human pain conditions and to dissect different
aspects of membrane excitability and synaptic translation (Narahashi, 2001; Guzman et al., 2007).
The in vitro methods described below use as endpoints some physical parameters resulting from
this blockage, such as cell or organ voltage. Reported inhibitory concentrations (IC50) for blocking of
the response by TTX and analogues in in vitro systems are presented in Table 8. No information is
available on the origin and the purity of the extracts.
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3.2.4. Relative potency of TTX analogues
Relative potencies (RPs) for TTX analogues, potentially standardised into toxic equivalency factors
(TEFs), are required to estimate the total toxicity of a sample based on all analogues identiﬁed and
quantiﬁed. The information available on the relative potencies of TTX analogues is rather scarce but
includes the analogues thus far detected in bivalves and gastropods in EU waters (11-norTTX-(6)-ol (S/R),
4-epiTTX, 4,9-anhydroTTX and 5,6,11-deoxyTTX, see Section 1.2.3). A partial list can be established
based on literature and was recently also presented in a Joint FAO/WHO technical paper (FAO/WHO,
2016) and a corresponding publication (Botana et al., 2016) Data on additional analogues were found in
the literature, but some of these were on synthetic analogues, not occurring naturally and are therefore
not included. The data and estimated RPs are presented in Table 9.
In most cases, details on the study and interpretation of the results were very limited. It is also
evident that the way lethality in mice was presented is rather diverse using parameters like MLD, LD50,
LD99, IC50 (all in lg/kg bw) or toxic potency (MU/mg compound). In this regard, the CONTAM
Panel also noted that the use of the term MLD seems highly variable and confusing. Kao and Fuhrman
(1963) reported MLD, LD50 and LD100 values for TTX after i.p. treatment of CF#1 mice of 8, 10 and
12 lg/kg bw, using seven doses and 6–16 animals per dose. This is in agreement with the fact that
the MLD is the minimum lethal dose, i.e. the lowest dose that can kill a mouse (see also Section 3.2.2
on toxicity). However, Yotsu-Yamashita and colleagues refer to the MLD as being the LD99
Table 8: In vitro IC50 values for blocking 50% of the response for TTX and analogues
Compound IC50 Test system Reference
TTX 5.2 nM at pH 7.80
14.2 nM at pH 8.80
Squid axon Hu and Kao (1986)
3.8 nM at pH 6.50 and 7.25
4.3 nM at pH 8.25
Frog muscle Yang and Kao (1992)
4.1 nM at pH 7.25 Frog muscle Yang et al. (1992)
25 nM  2.4 (Nav1.4) Oocytes of Xenopus sp.
injected with RNA to express
hNav1.4
Chahine et al. (1994)
4.3  0.92 nM Oocytes of Xenopus sp.
injected with RNA to express
rat peripheral sodium channel
Sangameswaran et al. (1997)
0.4 and 1.6 nM (Nav1.6)
In two oocytes
Oocytes of Xenopus sp.
injected with rRNA to express
rNav1.6
Dietrich et al. (1998)
7.8  1.3 nM (Nav1.2)
2.0  0.4 nM (Nav1.3)
4.5  1.0 nM (Nav1.4)
1,970  565 nM (Nav1.5)
3.8  1.5 nM (Nav1.6)
5.5  1.4 nM (Nav1.7)
1,330  459 nM (Nav1.8)
Oocytes of X. laevis injected
with RNA to express rNav1.2,
rNav1.3, rNav1.4, hNav1.5,
mNav1.6, hNaV1.7 or rNav1.8
Rosker et al. (2007)
17.1  1.2 nM (Nav1.4)
18.6  1.0 nM (Nav1.7)
CHO cells transfected with
cDNA encoding rNav1.4 or
hNaV1.7
Walker et al. (2012)
4-epiTTX 13.2 nM at pH 7.80 Squid axon Kao and Yasumoto (1985)
6-epiTTX 96 nM at pH 7.25 Frog muscle Yang et al. (1992)
11-deoxyTTX 445 nM at pH 7.25 Frog muscle Yang et al. (1992)
4,9-
anhydroTTX
298 nM at pH 7.80 Squid axon Kao and Yasumoto (1985)
1,260  121 nM (Nav1.2)
341  36 nM (Nav1.3)
988  62 nM (Nav1.4)
78,500  11,600 nM (Nav1.5)
7.8  2.3 nM (Nav1.6)
1,270  251 nM (Nav1.7)
> 30,000 nM (Nav1.8)
Oocytes of X. laevis injected
with RNA to express rNav1.2,
rNav1.3, rNav1.4, hNav1.5,
mNav1.6, hNaV1.7 or rNav1.8
Rosker et al. (2007)
IC50: inhibitory concentration blocking 50% of the response; TTX: tetrodotoxin.
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(Yotsu-Yamashita M., personal communication, Tohoku University, Sendai), which is in line with
Noguchi and Arakawa (2008) stating that it is the dose killing 100% of the mice. The dose that killed
only half of the mice was indicated as the LD50 and should thus be lower than the LD99. The study by
Kao and Fuhrman (1963) shows that the actual values for these parameters, at least for TTX, are
within a very small dose range (8–12 lg/kg bw) after i.p. treatment. It should also be pointed out that
in many studies the number of mice used is not indicated, and that in others only few mice were
injected with the analogue, probably due to the small amount available. As an example, the study on
6,11-dideoxyTTX reports an IC50 of 7.5 lg/kg bw for the dose that killed one of the two mice treated
(Jang and Yotsu-Yamashita, 2007). Doses of 4 and 15 lg/kg bw killed none or both of the two mice,
respectively. For 5,6,11-deoxyTTX, death was reported to occur after a period much longer than the
30 min, on which the MLD of 0.2 lg (1 MU) for TTX in the MBA is normally based. This supports the
observations of Vlamis et al. (2015) with contaminated and spiked blank mussels, showing the death
of mice after several hours and at TTX levels corresponding to exposures below the MLD. Nakamura
and Yasumoto (1985) reported lethal potencies for two analogues, 4,9-anhydroTTX and 4-epiTTX as
being 92 and 710 MU/mg, and compared them with the lethal potency of TTX being 4,500 MU/mg.
These values can be converted into the amount of compound corresponding to 1 MU, being
respectively 10.9, 1.4 and 0.22 lg/MU, the MU being the minimum amount that would kill a 20 g
mouse within 30 min. Corresponding RPs for these two analogues would thus be 0.02 and 0.16.
The RPs shown in Table 9, were estimated by comparing the lethality parameter obtained for the
analogue with the appropriate parameter for TTX (set at 1), i.e. lethality TTX/lethality analogue. A
lower value thus indicates a lower potency. The CONTAM Panel noted that correction for the molecular
weight would result in a small difference (up to 15%) for some values but for many analogues not be
visible in the rounded values.
Table 9: Lethal doses and relative potencies (RPs) for TTX and some of its analogues in mice, in most cases after i.p.
treatment
Compound Parameter RP
Molecular
weight
Reference
i.p. LD50 (lg/kg bw)
TTX 10 1 319.1 see Table 7, Kao and Fuhrman (1963)
11-deoxyTTX(c) 70 0.14 303.1 Yasumoto et al. (1988)
6-epiTTX(c) 60 0.17 319.1 Yasumoto et al. (1988)
11-norTTX-6(S)-
ol(e)
54 0.19 289.1 Yotsu et al. (1992)
5-deoxyTTX(c) 970 0.01 303.1 Satake et al. (2014)
i.p. LD100/99
(a) (lg/kg bw)
TTX 12 1 319.1 Kao and Fuhrman (1963)
11-oxoTTX(c) 16 0.75 335.1 Yotsu-Yamashita and Mebs (2003)
11-norTTX-6(R)-
ol(c)
70 0.17 289.1 Endo et al. (1988)
i.p. Lethal potency (MU/mg)
TTX 4,500 1 319.1 Nakamura and Yasumoto (1985)
4,9-
anhydroTTX(d)
92 0.02 301.1 Nakamura and Yasumoto (1985)
4-epiTTX(d) 710 0.16 319.1 Nakamura and Yasumoto (1985)
i.p. MLD(b) (lg/kg bw)
TTX 8 1 319.1 Kao and Fuhrman (1963)
5,6,11-
deoxyTTX(f)
750 0.01 271.1 Yotsu-Yamashita et al. (1995)
i.v. MLD(b) (lg/kg bw)
TTX 8 1 319.1 Tsuda et al. (1964)
Tetrodonic acid(g) > 300,000 0.00 319.1 Tsuda et al. (1964)
i.p. IC50 (lg/kg bw)
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Table 10 describes relative potencies of TTX analogues as determined in the Neuro2a-assay.
As can be seen in Table 10, some analogues were also tested in the Neuro-2a assay in the
presence of ouabain/veratridine, using the conversion of WST (2-[4-iodophenyl]-3-[4-nitrophenyl]-5-
[2,4-disulfophenyl]-2H-tetrazolium, monosodium salt), as the end-point for viability. RPs are based on
the EC50 (in nM). This revealed for 11-deoxyTTX a 10-fold lower RP than in the MBA, while for
11-oxoTTX, the relatively high potency was conﬁrmed, although a factor of 3 higher in the Neuro-2a
assay, for 6,11-dideoxyTTX, the RP was rather similar.
3.2.4.1. Concluding remarks on relative potencies
It can be concluded that various TTX analogues have been tested in mice, most of them by i.p.
injection. The Panel noted that in general the description of the studies is rather limited and that there
are various ways in which the toxicity was expressed (LD50, LD99, IC50, MLD and lethal potency).
There were some additional studies with the Neuro-2a cell assay, to some extent supporting the data
from the mouse bioassay. Overall, the data should be considered as indicative and may at best allow
an order of magnitude estimation of the relative potencies. Nevertheless, these studies show that most
analogues are much less toxic than TTX.
As can be seen in Table 9 estimated relative potencies, based on comparison with the most appropriate
parameter for TTX, were 0.75 for 11-oxoTTX, 0.14 for 11-deoxyTTX, 0.19/0.17 for S/R 11-norTTX-(6)-ol,
0.16 for 4-epiTTX, 0.02 for 4,9-anhydroTTX and 0.01 for 5,6,11-deoxyTTX. The CONTAM Panel noted that
the uncertainties associated with estimation of these relative potencies are very high.
3.2.5. Consideration of setting a health-based guidance value (HBGV)
TTX is a potent neurotoxin, causing inhibition of nerve and muscle conduction by blocking sodium
channels, with symptoms occurring within minutes to hours of consumption of contaminated foods.
Because of the acute toxicity of TTX, the CONTAM Panel concluded that an ARfD should be
established, for the amount of TTX that can be ingested in a period of 24 h or less without appreciable
health risk to consumers (as deﬁned by OECD, 2010). Because of the overall limitations in the data
available, different possible approaches to derive an ARfD were considered which were i) the use of
the human intoxication data ii) extrapolation from STX and iii) the use of newly available data from an
acute oral toxicity study in mice.
Compound Parameter RP
Molecular
weight
Reference
6,11-dideoxyTTX 420 0.02 vs. LD50
TTX
287.1 Jang and Yotsu-Yamashita (2007)
i.p.: intraperitoneal; i.v.: intravenous; MLD: minimum lethal dose; TTX: tetrodotoxin.
Analogues given in bold were detected in marine bivalves or gastropods (those not detected in the EU are in addition also in italics).
(a): LD100 (lethal dose 100%) for TTX, LD99 (lethal dose 99%) for the two analogues.
(b): The use of the term MLD is unclear; see Section 3.2.2 on toxicity.
(c): No details provided.
(d): Lethal potencies, standardised for TTX according to Kawabata (1978) (5 mice/dose). No MLD (minimum lethal dose) or LD50 provided.
(e): Acetate form, no details provided.
(f): Mentioned in a footnote, deaths occurred between 5 and 24 h.
(g): MLD, based on Mongrel mice. In Tsuda (1966), values are reported as LD50 (lethal dose 50%) values.
Table 10: Relative potencies (RPs) for TTX analogues, as determined in the Neuro2a-assay
Compound EC50 (nM) RP Reference
TTX 2.1
4.6
4.7
1 Kudo et al. (2014)
Yotsu-Yamashita et al. (2003)
Saruhashi et al. (2016)
11-deoxyTTX 130
270
0.016
0.017
Kudo et al. (2014)
Yotsu-Yamashita et al. (2003)
6,11-dideoxyTTX 400 0.056 Kudo et al. (2014)
11-oxoTTX 2.9 1.6 Saruhashi et al. (2016)
6-deoxyTTX 6.5 0.32 Kudo et al. (2014)
EC50: Effective concentration 50%.
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It is often reported that the minimum lethal dose of TTX for humans is in the region of 40 lg/kg bw
and that the lowest dose resulting in symptoms is 4 lg/kg bw. However, the CONTAM Panel was not able
to identify the origins of these reports, and therefore, it is unknown how many cases were assessed in
reaching these conclusions, nor whether the ascertainment of dose in the cases was robust. The reports
of TTX toxicity generally do not allow estimation of the dose of TTX that resulted in the symptoms in
humans. Five recent reports refer to serious symptoms, and in some instances fatalities, at doses in the
range of 4–42 lg/kg bw. There is considerable uncertainty in these estimates, relating to whether the
food in which TTX was measured was representative of that consumed, how much of the food was
consumed and the bodyweight of the affected subjects. Perhaps the most reliable data are from
a case, in which pufferﬁsh was cooked in soup, and it was possible to measure the TTX concentration
in unconsumed soup. In this incident, a dose of 42 lg/kg bw resulted in severe symptoms, whereas
14 lg/kg bw led to less severe symptoms not requiring hospitalisation. However, even with this case
there is uncertainty regarding the estimation of the amount of soup consumed and the bodyweights to
the affected individuals (the pufferﬁsh was purchased from an Asian market in the USA). Therefore, the
CONTAM Panel concluded that the human data did not provide a standalone basis for derivation of an
ARfD because of the considerable uncertainties associated with the reported effect doses.
The mode of action of TTX is similar to that of STX, with some differences in the afﬁnity for the
different subtypes of voltage-gated sodium channels (Nav), but not identical to that of STX. The
CONTAM Panel previously established an ARfD of 0.5 lg STX equivalents/kg bw (EFSA CONTAM Panel,
2009). This was based on the LOAEL in the region of 1.5 lg STX equivalents/kg bw, derived from the
available reports of human poisoning, affecting more than 500 individuals. The Panel noted that many
individuals did not suffer adverse reactions at much higher intakes, and therefore, it was expected that
this LOAEL was very close to the threshold for effects in the most sensitive individuals. The
Panel therefore applied a factor of 3 to the LOAEL in order to estimate a NOAEL of 0.5 lg STX
equivalents/kg bw but no additional factor for variation among humans. The database for STX is much
more extensive than that for TTX. The Panel also noted that the difference in toxic potency observed
after i.p. vs oral treatment in mice was also rather similar between STX (i.p. and oral LD50 values of
9.0–11.6 and 260–263 lg/kg bw respectively; EFSA CONTAM Panel, 2009) and TTX (i.p. and oral LD50
values of 8.2–10.7 and 232–532 lg/kg bw, respectively; see Section 3.2.4 on relative potencies),
suggesting no large differences in toxicokinetics, at least in mice. Extrapolating from STX to TTX would
imply an ARfD of 0.5 lg/kg bw.
The newly available oral toxicity data on TTX in mice provide an acute LOAEL of 125 lg/kg bw
(incidence 9/9 animals), and an acute NOAEL of 75 lg/kg bw based on apathy. However, there is a
narrow interval between the dose where lethality occurred (250 lg/kg bw) and the dose where there
was no apathy observed. The observations precluded the application of a benchmark dose (BMD)
modelling for apathy. However, lethality could be modelled and resulted in a BMDL10 of 112 lg/kg bw
which is only slightly above the NOAEL for apathy (75 lg/kg bw, for details on the BMD calculations see
Appendix D). Furthermore, with a group size of nine individuals, it cannot be excluded that at that a
dose of 75 lg/kg bw no effects can occur. Therefore, the CONTAM Panel decided to use the next lower
dose tested (25 lg/kg bw) as the reference point to derive an ARfD. This dose is 4.5-fold lower than
the BMDL10 for lethality. Applying a standard uncertainty factor (UF) of 100, an ARfD of 0.25 lg/kg bw
was derived. The CONTAM Panel noted that the ARfD is 16-fold lower than the dose at which severe
effects have been observed in humans (4 lg/kg bw) and is 2-fold lower than the ARfD for STX.
The CONTAM Panel noted that other TTX analogues may have a similar mode of action. Such
analogues have been detected in marine bivalves and gastropods, like 11-oxoTTX (not in European
waters), 4-epiTTX, 5,6,11-trideoxyTTX, 4,9-anhydroTTX and 11-norTTX-6-ol (R- and/or S-form). Some
studies isolated these analogues and tested them by i.p. or i.v. injection in mice for lethality. With the
exception of 11-oxoTTX, the analogues seem at least 5- to 100-fold less toxic than TTX. Relative
potencies have been estimated for TTX analogues based on these studies (see Section 3.2.4). The
Panel noted that the description of the methods, the results and derivation of a lethal dose is rather poor
in these studies. Nevertheless they should allow an order of magnitude estimation of the toxic potency.
Based on the detected levels, these analogues (with the possible exception of 11-oxoTTX) appear to
contribute very little to the toxicity, when assuming similar kinetics. The Panel points out that the
derivation of relative potencies as described in Section 3.2.4 is associated with very high uncertainties.
The ARfD of 0.25 lg/kg bw is therefore a group ARfD that should apply to TTX and its analogues
taking into account their estimated relative potencies as compared to TTX, being 0.75 for 11-oxoTTX,
0.14 for 11-deoxyTTX, 0.19/0.17 for S/R 11-norTTX-(6)-ol, 0.16 for 4-epiTTX, 0.02 for 4,9-anhydroTTX
and 0.01 for 5,6,11-deoxyTTX.
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No data were available to consider possible longer term effects of TTX, or to establish a tolerable
daily intake (TDI).
3.3. Occurrence data
3.3.1. Previously reported occurrence data
In this section, the reports of occurrence of TTX and its analogues (TTXs) found in marine bivalves
and gastropods in European waters are summarised and the results are shown in Table 11. Summaries
of studies from non-European waters are shown in Table C.1 in Appendix C and a brief overview is
given below. It should be noted that 4,9-anhydroTTX (see Table 11) and anhydroTTX (see Table C.1 in
Appendix C) are considered to be the same analogue.
Reports of TTX from human poisoning cases are already mentioned in Section 3.2.2 on toxicity and
Table B.1 of Appendix B and are therefore not included in Table 11 and Table C.1. For the European
studies, the results are primarily given as concentrations of TTXs while for the non-European studies
results are primarily given in MU. Only in few of the latter cases, TTXs are quantiﬁed, and in these
cases, the results are often not given exactly. Results given in mg/kg and MU/g can be converted to
each other as 1 MU was shown to correspond to 0.22 lg TTX except when otherwise speciﬁed such as
in Hwang et al. (2005) where 1 MU is assumed to correspond to 0.178 lg TTX. It should be noted
that in some studies the presence of other marine toxins is indicated and therefore not all the toxicity
can be assigned to TTX and its analogues.
The ﬁrst ﬁnding of TTX and its analogues in marine gastropods from European waters was the
poisoning case reported by Rodriguez et al. (2008; see Section 3.2.2). Here, TTX and
5,6,11-trideoxyTTX were found in the digestive gland (DG), while neither of the substances were
found in the ﬂesh.
The ﬁrst report on ﬁndings of TTX and its analogues in bivalves in European waters was by Turner
et al. (2015). TTX and four of its analogues were found in mussels (Mytilus edulis) and Paciﬁc oysters
(Crassostrea gigas), harvested from the south coast of England in 2013 and 2014. The results are
shown in Table 11. In general, TTX was always found when its analogues were found except in two
samples, where 5,6,11-trideoxyTTX was the only ﬁnding. TTX and six TTX analogues (4-epiTTX;
5,6,11-trideoxyTTX; 4,9-anhydroTTX; 11-norTTX-6-ol; mono-deoxyTTX; and 11-oxoTTX) were included
in the method and quantitation of TTX analogues was conducted assuming the same analytical
response factor as TTX. In the absence of standards, an extract from a grey side-gilled sea slug
studied by McNabb et al. (2010) was used for identiﬁcation of analogues. Data on the UK samples are
included in the EFSA database.
Vlamis et al. (2015) have investigated the presence of TTXs in mussels (Mytilus galloprovincialis)
from marine waters around Greece. Also, a few samples of Venus clams (Venus verrucosa) have been
analysed TTXs were found in mussels from 2012 that were sampled as part of the ofﬁcial Greek
control program for shellﬁsh. Four out of six samples were tested positive in the Yasumoto 1978
protocol for lipophilic toxins (Yasumoto et al., 1978) which is based on an initial extraction with
acetone, potentially followed by a partitioning step to separate lipophilic toxins from the more
hydrophilic toxins. According to Vlamis et al. (2015), the test with the acetone extract presented an
atypical nervous symptomology prior to mice death. The four samples were tested negative in the MBA
for PSP and < LOD of 0.1 mg/kg for ASP toxins. All six samples were then analysed for the presence of
TTXs by LC–MS. Mainly digestive glands (DG) were analysed but also a single sample of whole ﬂesh
(WF = whole body or any part edible, see deﬁnitions in Regulation 2074/200512). This revealed the
presence of TTXs at levels between 0.0462 and 0.203 mg/kg in DG and 0.179 mg/kg in WF (see
Table 11). Besides, TTX also 4-epiTTX and 4,9-anhydroTTX were identiﬁed. Subsequently, control data
from 2006 to 2012 were reviewed and 17 samples (16 mussels and 1 Venus clam) with atypical
positive results to asymptomatic negative results in the MBA protocol (Yasumoto et al., 1978) were
selected and DG or WF from these samples were analysed. The concentrations ranged from 0.047 to
0.092 mg/kg in mussels DG only for TTX, and was 0.080 mg/kg in the single WF sample analysed. In
clam DG, the sum of TTXs was 0.177 mg/kg. In all 17 samples, 4-epiTTX and 4,9-anhydroTTX were
12 Commission Regulation (EC) No 2074/2005 of 5 December 2005 laying down implementing measures for certain products
under Regulation (EC) No 853/2004 of the European Parliament and of the Council and for the organisation of ofﬁcial controls
under Regulation (EC) No 854/2004 of the European Parliament and of the Council and Regulation (EC) No 882/2004 of the
European Parliament and of the Council, derogating from Regulation (EC)No 852/2004 of the European Parliament and of the
Council and amending Regulations (EC) No 853/2004 and (EC) No 854/2004. OJ L 338. 22.1.2005. p. 27–59.
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below the LOD. In 2014, samples of mussels were taken during the period April–July from the same
water as the previously positive samples and WF were analysed. The concentrations ranged from
0.025 to 0.043 mg/kg only for TTX (4-epiTTX and 4,9-anhydroTTX were below the LOD). Also,
randomly collected routine samples of shellﬁsh (15 mussels, 1 Venus clam) in June–July 2014 were
analysed but no TTXs were found. All the Greek results are shown in Table 11 and the results are also
included in the EFSA database. In all the studies, concentrations between LOD and LOQ are quantiﬁed
and included in the sum of TTXs. Certiﬁed TTX together with naturally contaminated samples provided
retention times, and these were used for identiﬁcation of 5,6,11-trideoxyTTX, 5-deoxyTTX, 11-
deoxyTTX, 11-norTTX-6(R)-ol and 11-norTTX-6(S)-ol, but none of those analogues were found.
In the Netherlands, the possible presence of TTX and its analogues was investigated in mussels and
oysters sampled in 2015 (RIVM-RIKILT, 2015). A total of 152 shellﬁsh samples were analysed,
originating from different Dutch production areas. Only in samples collected from certain parts in the
Eastern Scheldt estuary, TTX levels exceeded the LOD of 3 lg TTX/kg. Altogether, 55 samples were
collected from these areas, namely 12 samples of oysters and 43 samples of mussels. Of these 55
samples, 15 samples had levels of TTX above the LOD, and 11 had concentrations above the LOQ, in
this ﬁrst report being 10 lg/kg. The maximum concentration found was in oysters at a level of
0.124 mg TTX/kg. These samples are included in the EFSA database which also includes new samples
from 2016 which showed concentrations up to a maximum of 0.253 mg TTX/kg (see Section 3.3.2 on
current occurrence).
A total of 134 samples of marine organisms, including gastropods and bivalves, were collected
along the Portuguese coast from July 2009 to November 2010 and analysed for the content of TTXs
(Silva et al., 2012). In samples of the gastropods Gibbula umbilicalis, Monodonta lineata and Charonia
lampas (trumpet shell), TTX, 4-epiTTX, mono-deoxyTTX and 5,6,11-trideoxyTTX were found (see
Table 11). The two analogues 4-anhydroTTX and 11-norTTX-6-ol were looked for but not found. The
term mono-deoxyTTX is used because it could not be identiﬁed at which carbon the oxygen was lost.
Quantiﬁcation of TTX and its analogues were calculated against a TTX standard assuming that all the
toxins had the same molar response. The gastropod sample from Rodriguez et al. (2008) and a
positive sample of Lagocephalus sceleratus were used as a reference.
All other publications about ﬁndings of TTXs in marine gastropods and bivalves are from samples
from New Zealand and Asia (i.e. China, Japan, Vietnam and Taiwan). McNabb et al. (2014) detected
TTXs in a bivalve (Paphies australis) at levels up to 0.8 mg/kg. In all the publications about Asian
samples, TTXs are reported in gastropods not only in Nassarius spp. but also in species of the genera
Oliva, Babylona, Choronia and Zeuxis, TTX was found. In species of genera Nassarius, Baylonia and
Charonia, also TTX analogues were found (see Appendix C Table C.1). In the studies from Asia, the
levels were measured with the MBA for either TTX or PSP and expressed as MU/g. Quantiﬁed mean
concentrations in gastropods ranged from 4 MU/g to 370 MU/g in DG.
As it can be seen from Table 11 and Table C.1 in Appendix C, the concentrations of TTXs in
bivalves and gastropods from European waters are much lower than in samples from non-European
waters, with the exception of the snail causing the intoxication case in Spain. The concentration of TTX
observed in positive samples from European waters is between 0.003 and 0.253 mg/kg, while it is
between 0.88 mg/kg and 81.4 mg/kg in samples from non-European waters. Neither from the
European nor from the non-European samples is it possible to compare the contents in different
tissues. In the European samples, only Vlamis et al. (2015) reported about analysis of DG and WF in a
limited number of samples and concluded that there were no differences in the concentrations. In a
few of the non-European samples edible portion and DG are analysed in gastropods but concentrations
in DG are both higher or lower than in other tissues (see Table C.1). It is therefore not possible to
conclude, across the studies, which tissues or parts have the highest concentrations of TTXs in
bivalves.
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3.3.2. Current occurrence data
A total of 1,677 samples of marine bivalves analysed for the presence of TTX were available in the
ﬁnal dataset. Most of the available data (n = 1,544 or 92%) were either non-detected or non-
quantiﬁed values. In case of analogues, altogether only 62 of the total 6,590 reported values (0.94%)
were numerical values. Taking into account that few data were available on analogues combined with
relatively low levels and low potencies of the detected analogues, the CONTAM Panel decided not to
include them in the exposure assessment.
The number of analysed and quantiﬁed values for TTX and its analogues are presented in Table 12.
In most of the reported samples, the whole ﬂesh of bivalves was analysed. This includes the meat of
the animals and their digestive glands. Only Greece reported some results where digestive glands were
analysed separately.
The Greek data differentiated between the following cases:
1) Mussel digestive gland – only digestive gland was analysed (n = 28).
2) Mussel digestive gland/whole ﬂesh – both tissues were analysed separately, deriving from
the same sample (same batch of mussels). The result was considered the same for both
(n = 8) by the data provider, thus these results were reported only once.
3) Mussel whole ﬂesh – digestive gland and meat was analysed together (n = 17).
Similarly, besides the above described samples, two samples for Venus clam (one for digestive
gland/whole ﬂesh and one for digestive gland only) were reported from Greece.
Considering the low number of quantiﬁed levels in the digestive gland among the total number of
samples and due to very limited data on the distribution of TTX between the digestive gland and ﬂesh
of the animal (Table C.1, Appendix C), the CONTAM Panel assumed that there was no difference in
TTX content of the different tissues and therefore decided to include all data. Samples were analysed
by LC–MS/MS, LC–MS (quadrupole) and LC–MS/MS (triple quadrupole).
Table 12 presents an overview about the samples received from EU MS.
Table 13 provides an overview of the descriptive statistics of the data by the type of bivalves. The
UB median and 95th percentile levels reported to EFSA, taking into consideration all received data on
TTX in bivalves, were 5.9 and 28 lg/kg, respectively. Concerning the different types of water molluscs,
the highest UB mean of 10.8 lg/kg was reported for clams, and the highest 95th percentile level of
Table 12: Number of analysed, non-detected, non-quantiﬁed and quantiﬁed values for TTX and its
analogues
Country Parameter
Total analysed
Non detected or
non quantiﬁed value
(< LOD or < LOQ)
Quantiﬁed value
N N N
United Kingdom TTX 1,092 1,057 35
11-norTTX-6-ol 1,080 1,079 1
11-oxoTTX 1,080 1,080 0
4,9-anhydroTTX 1,080 1,073 7
4-epiTTX 1,080 1,058 22
5,6,11-trideoxyTTX 1,080 1,053 27
MonodeoxyTTX 1,080 1,080 0
Greece(a) TTX 55 16 39
4,9-anhydroTTX 55 54 1
4-epiTTX 55 51 4
Netherlands(b) TTX 530 471 59
LOD: limit of detection; LOQ: limit of quantiﬁcation; TTX: tetrodotoxin.
(a): According to the data provider, the 55 samples were analysed for 5,6,11-trideoxyTTX; 5-deoxyTTX; 11-deoxyTTX; 11-
norTTX-6(R)-ol; and 11-norTTX-6(S)-ol analogues as well. The results were either non-detects or non-quantiﬁed. These data
were not submitted to EFSA.
(b): According to the data provider, the 530 samples were analysed for 4,9-anhydroTTX and 4-epiTTX as well, where all the
results were either non-detects or non-quantiﬁed except for one level for 4-epiTTX in a sample of oysters (14.5 lg/kg).
These data were not submitted to EFSA.
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79 lg/kg was reported for oysters. Highest reported level among all data was 253 lg/kg in oysters,
highest reported level in mussels were 179 and 203 lg/kg for WF and DG, respectively.
Samples were taken with different sampling strategies as given by the data providers according to
the classiﬁcation of Standard Sample Description for Food and Feed (EFSA, 2010a). From the total
1,677 samples, 83 samples from the Netherlands were reported as suspect samples. In order to follow
a conservative approach, these samples were included as well in the exposure assessment.
The total of 1,677 samples taken between years 2006 and 2016 by the UK, Greece and the
Netherlands are presented in Table 14 according to sampling year. After discovery of the presence,
Greece performed some retrospective studies, looking at stored samples with false-positive results
(Vlamis et al., 2015).
For the 1,636 samples where the exact sampling date was reported, the seasonal variability of
occurrence of TTX was investigated. Most of the samples were taken in the period from June to
September. Number of samples by month, country and percentage of quantiﬁed values per month are
presented in Table 15.
Table 13: Statistics of occurrence data of TTX in marine bivalves sampled between 2006 and 2016
as provided by three European countries: the United Kingdom, the Netherlands and
Greece
Type of water mollusc
No. of
samples
% Left-censored
data
Mean
concentration
(lg/kg)
95th percentile
concentration
(lg/kg)(e)
LB MB UB LB MB UB
All water molluscs 1,677 92 4.1 5.0 5.9 28 28 28
Water molluscs (unspeciﬁed)(a) 12 100 0.0 0.3 0.5 – – –
Clam(b) 28 75 10.3 10.6 10.8 – – –
Cockle 95 100 0.0 0.8 1.6 0.0 2.5 5.0
Mussel(c) 1,084 93 3.8 4.8 5.7 30.1 30.1 30.1
Oyster 299 85 8.4 9.3 10.2 79.0 79.0 79.0
Scallop 61 100 0.0 0.3 0.5 0.0 0.3 0.5
Razor clam(d) 98 100 0.0 1.0 1.9 0.0 2.5 5.0
LB: lower bound; MB: middle bound; UB: upper bound.
(a): Non-speciﬁed bivalves.
(b): Includes hard clams, surf clams and Venus clams.
(c): Includes Mytilus edulis, Mytilus galloprovincialis.
(d): Includes ensis razor clams.
(e): 95th percentile concentration cannot be given when number of samples is less than 60.
Table 14: Total number of samples available for each sampling year by the respective country
Country
Year of sampling
2006 2008 2009 2012 2013 2014 2015 2016
United Kingdom 0 0 0 0 15 643 434 0
Greece 3 6 3 12 0 31 0 0
Netherlands 0 0 0 0 0 0 257 273
Total 3 6 3 12 15 674 691 273
Table 15: Number of samples taken by the reporting countries by months and proportion of
quantiﬁed values
Sampling month
Country Total
samples
No of quantiﬁed
values
% of quantiﬁed
values(a)UK NL GR
January 0 18 0 18 0 0
February 0 37 0 37 0 0
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The distribution of the analytical results per month in each country and all countries together are
shown in Figure 1. It is evident that in the UK and the Netherlands, contaminated samples were only
observed in the summer season. This was not the case in Greece, with contaminations also at the end
of the year.
Sampling month
Country Total
samples
No of quantiﬁed
values
% of quantiﬁed
values(a)UK NL GR
March 4 35 1 40 1 3
April 25 19 5 49 5 10
May 13 16 11 40 11 28
June 88 70 12 170 32 19
July 317 185 15 517 54 10
August 262 65 0 327 2 1
September 328 68 1 397 4 1
October 14 17 4 35 4 11
November 0 0 3 3 3 100
December 0 0 3 3 3 100
Sum 1,051 530 55 1,636 119
GR: Greece; NL: Netherlands; UK: United Kingdom.
(a): Percentage of quantiﬁed values out of the total samples taken in the given month.
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Figure 1: Distribution of TTX concentrations in European marine bivalves by months in the different
reporting countries
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3.4. Impact of food processing and storage
Very little information is available about the inﬂuence of processing on the concentration of TTX.
Although TTX is mentioned to be heat stable in various reviews, only one processing study has been
identiﬁed.
TTX is heat-stable and will not decompose during the traditional cooking process (Islam et al.,
2011). In other reviews (e.g. in Bane et al., 2014; Turner et al., 2015; FAO/WHO, 2016) it is also
stated that TTX is heat stable.
In the project ECsafeSEAFOOD13, the level of TTX in commercially available pufferﬁsh was assessed
after steaming of pufferﬁsh (Lagocephalus sceleratus). The gonads from a pufferﬁsh were steamed at
100°C for 10 min and then extracted and analysed. The concentrations measured were 14.34 mg TTX
equivalents/kg (w/w) in raw gonads as compared to 18.35 mg TTX equivalents/kg in cooked gonads.
The toxin was not decomposed by the treatment.
EFSA (2009a,d) has published opinions on the saxitoxin group and domoic acid and both kind of
toxins are hydrophilic similar to TTXs. According to these EFSA opinion, both for the saxitoxin group
and domoic acid, studies have shown that home cooking processes, such as boiling or steaming, can
reduce the level of toxins in shellﬁsh meat, due to partial leaching of the toxins into the cooking liquid.
3.4.1. Concluding remarks on food processing
It can be assumed that TTX will not be degraded during normal home-made cooking processes. No
data were identiﬁed on TTX analogues but since TTX and its analogues are chemically similar it can be
assumed that they will behave in the same way to processing.
3.5. Current exposure assessment
3.5.1. Consumption of marine bivalves
Since 2008, the CONTAM Panel adopted a series of opinions on the safety of marine biotoxins
(EFSA, 2008a–c, 2009a–e; EFSA CONTAM Panel 2009, 2010a–d). In all these opinions, in order to
assess the exposure, the CONTAM Panel used 400 g as a standard for a large portion of shellﬁsh meat
consumed in Europe. This standard amount was ﬁrst used in 2008, in the scientiﬁc opinion on okadaic
acid and analogues (EFSA, 2008b) and was based on consumption data from ﬁve Member States.
These food consumption data were derived from dietary surveys from 1985 carried out with different
methodologies, including food records (from 2 to 7 days) and food frequency questionnaires. In these
studies, the 95th percentiles consumption of shellﬁsh meat ranged from 70 to 465 g, whereas the
maximum reported portion sizes ranged from 239 to 1,500 g. However, the Panel noted that the
portion sizes of 1,000 and 1,500 g of shellﬁsh did not likely include only the edible part and could
include the shells as well.
The estimated 400 g large portion size was then reviewed in 2010 in a statement of the CONTAM
Panel, as in the meantime new food consumption data on shellﬁsh were made available to EFSA by
different EU countries, mainly within the EFSA Comprehensive Database. In particular, the 95th
percentile consumption of shellﬁsh meat ranged from 63 to 251 g in the EFSA Comprehensive
Database. This information was not considered sufﬁcient to warrant a revision of the CONTAM Panel’s
earlier established estimate on the consumption ﬁgure of 400 g shellﬁsh meat. The CONTAM
Panel based this decision on the uncertainty due to limited information on shellﬁsh consumption in
Europe and due to the limited representative data on shellﬁsh types other than mussels. In addition,
an appreciable uncertainty was highlighted in the 95th percentile consumption of shellﬁsh meat from
the Comprehensive Database, presenting a wide range of conﬁdence intervals.
Since then, the Comprehensive Database has been updated and the current state is that
consumption of bivalves was reported in 29 surveys from 17 countries out of the 51 surveys from 23
countries for which food consumption data are available. Number of consumption days, the mean and
95th percentile for consumed quantities are reported in Annex A for water molluscs and for each
individual type of bivalves, i.e. mussels, clams, razor clams, oysters and cockles.
As suggested in the guidance on the Use of the EFSA Comprehensive European Food Consumption
Database in Exposure Assessment (EFSA, 2011a), the 95th percentile has been considered as reliable
only when the number of consumption days is at least 60. According to the above-mentioned
13 http://www.ecsafeseafood.eu/
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document, percentiles calculated over a number of subjects/days lower than 60 (for the 95th
percentile) and lower than 300 (for the 99th percentile) have considerable uncertainty and may not be
statistically robust.
When considering all water molluscs together (so without differentiating between individual
species), and all population groups, mean consumption of shellﬁsh meat (in a single day) ranged from
1.2 to 450 g/day (0.02–6.7 g/kg bw per day), taking into account consumption days 1–404 for the 68
population groups in the 29 surveys. The 95th percentile ranged from 5.6 to 180 g/day (0.07 to 3.27
per kg bw) when taking into account the seven population groups in ﬁve surveys with at least 60
consumption days per population group.
It needs to be pointed out that the highest means are associated with a high uncertainty because
they are based on results from population groups with only 1 or 2 consumption days.
Only in the adult group from the surveys of Spain and France, the number of consumption days for
bivalves exceeded 300, allowing calculation of the 99th percentile, being 95 and 210 g/day (1.4 and
3.8 g/day per kg bw), respectively. Only in 9 out of the 2,102 days the consumption of bivalves
reported in the Comprehensive Database exceeded 400 g/day.
The CONTAM Panel noted that the consumption data on marine gastropods are limited (32
consumption days in two surveys on whelks and winkles).
3.5.2. Results from current exposure assessment
The results of the probabilistic exposure assessment for TTX are presented in detail in Annex B.
According to the guidance on the ‘Use of the EFSA Comprehensive European Food Consumption
Database in Exposure Assessment’ the 95th percentile can be considered statistically robust if it is
calculated with surveys where the number of consuming days is at least 60 per age group per survey.
Similarly, the 99th percentile can be taken into account if the number of consuming days is at least
300. Thus, in the results presented below the calculated mean values are applicable for all the surveys,
but the 95th percentiles are calculated for only those where consuming days were at least 60 per age
group per survey.
Overall, considering consuming days only the average acute exposure level ranged from 0.00 to
0.09 lg/kg bw, and 95th percentile acute exposure level ranged from 0.00 to 0.03 lg/kg bw
depending on the age group and survey. It should be noted that the studies with the highest average
intakes did not allow the calculation of a 95th percentile as they are based on few consumption days.
In the ‘adult’ group, the average acute exposure level ranged from 0.00 to 0.01 lg/kg bw and the
95th percentile acute exposure levels ranged from 0.00 to 0.03 lg/kg bw.
In the ‘adolescent’ group, the average acute exposure level ranged from 0.00 to 0.01 lg/kg bw.
The 95th percentile acute exposure level was available at one survey where it was 0.03 lg/kg bw.
Average acute exposure level in the ‘other children’ group ranged from 0.00 to 0.03 lg/kg bw. The
95th percentile acute exposure level was not calculated as the surveys were below 60 subjects/
consuming days.
Average acute exposure level in the ‘toddlers’ group ranged from 0.00 to 0.02 lg/kg bw. The 95th
percentile acute exposure level was not calculated as the surveys were below 60 subjects/consuming
days.
The highest estimated average exposure level of 0.09 lg/kg bw occurred in the ‘elderly’ group.
Regarding the different types of water molluscs (see Annex B, worksheet ‘Group’), the highest
mean exposure level for clams was 0.02 lg/kg bw, corresponding values for mussels and oysters were
0.03 and for 0.09 lg/kg bw, respectively.
For razor clams, scallops, cockles and non-speciﬁed water molluscs, average acute exposure was 0.
The highest 95th percentile exposure, considering only the consumption days, was estimated for
oysters (0.08 lg/kg bw).
Acute exposure to TTX was also estimated by multiplying the above mentioned large portion size of
400 g by the 95th percentile of TTX occurrence data and divided by a standard body weight of 70 kg.
In this case, the acute exposure ranged from 0.03 to 0.45 lg/kg bw depending on the types of water
molluscs. Results are presented in Table 16.
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3.6. Risk characterisation
When considering consumption days only, the average acute exposure to TTX ranged from 0.00 to
0.09 lg/kg bw, the P95 from 0.00 to 0.03 lg/kg bw. It should be noted that only ﬁve surveys allowed
the estimation of a P95 for one or more age classes or bivalve type, and this did not include the
surveys with the highest average intakes where the estimation is based on only few observations.
In previous opinions on marine biotoxins, the CONTAM Panel used a large portion size of 400 g.
This portion size is higher than the highest P95 observed in food consumption surveys, roughly by a
factor of two. Nevertheless, the Panel decided to use this 400 g as a conservative approach.
Combining this intake with the P95 of the occurrence data for the whole group of water molluscs,
being 28 lg/kg, and assuming a body weight of 70 kg, would result in an intake of 0.16 lg/kg bw.
The highest exposure was estimated for oysters (P95 level of 79 lg/kg), showing an estimated intake
of 0.45 lg/kg bw. For mussels, this value was 0.17 lg/kg bw.
The average and 95th percentile exposure levels did not exceed the group ARfD of 0.25 lg/kg bw
regarding the consumption days or subjects except that for consumption of a large portion of oysters
(exposure was 0.45 lg/kg bw). Consequently, the CONTAM Panel did not identify a concern for the
general population upon consumption of marine bivalves from European waters, with the possible
exception of a large portion of oysters with high TTX level.
When combining the large portion size of 400 g, consumed by a person of 70 kg bw, with the ARfD
of 0.25 lg/kg bw, it can be estimated that the highest level in shellﬁsh not expected to result in
adverse effects in consumers would be 70 x 0.25/0.4 = 44 lg/kg raw shellﬁsh meat.
The Panel noted that some samples reported to EFSA exceeded this level, potentially implying a
health risk for some of the observed levels in case of a large portion size.
3.7. Uncertainty analysis
In human case studies, estimated TTX doses are associated with a high level of uncertainty, due to
e.g. undeﬁned amounts of actual consumption, the fact that material analysed might not represent
what has actually been consumed, and inaccurate concentration estimates of TTX due to the method
used or the lack of certiﬁed standards. Using the mouse bioassay to determine the TTX content in food
consumed or human samples does not enable to discriminate whether indeed TTX or STX caused the
effects. There is uncertainty on the MLD of 2 mg per person that is reported in the literature but for
which no underlying data could be identiﬁed. The use of the term MLD in human, but also in animal
studies, is inconsistent throughout the literature. Due to these overall uncertainties, the CONTAM
Panel decided not to base the ARfD on results from human case studies.
Table 16: Acute exposure to TTX by type of bivalve calculated with deterministic approach, based
on a 400 g large portion size and P95 occurrence levels
Type of water mollusc N
95th percentile
concentration (lg/kg)(e) UB Exposure
(lg/kg bw per day)
LB MB UB
Water molluscs (all) 1,677 28 28 28 0.16
Water molluscs (unspeciﬁed)(a) 12 – – – –
Clam(b) 28 – – – –
Cockle 95 0.0 2.5 5.0 0.03
Mussel(c) 1,084 30.1 30.1 30.1 0.17
Oyster 299 79.0 79.0 79.0 0.45
Scallop 61 0.0 0.3 0.5 0.00
Razor clam(d) 98 0.0 2.5 5.0 0.03
bw: body weight; LB: lower bound; MB: middle bound; N: number of samples; UB: upper bound.
(a): Non speciﬁed bivalves.
(b): Includes hard clams, surf clams and Venus clams.
(c): Includes Mytilus edulis, Mytilus galloprovincialis.
(d): Includes ensis razor clams.
(e): 95th percentile cannot be given when number of samples is less than 60.
TTX in marine bivalves and gastropods
www.efsa.europa.eu/efsajournal 41 EFSA Journal 2017;15(4):4752
Toxic effects of TTX, observed after a single intragastric dose in mice were used to derive the group
ARfD. The applied method excludes absorption of the compound in the very upper part of the
digestive system (i.e. mouth and oesophagus), which based on the rapid onset of effects, seem
potential sites of TTX absorption in humans. The CONTAM Panel also noted that the observation period
in the study (2 h) is relatively short, even for an acute toxicity study, and that deaths have been
described in mice after 2 h following i.p. treatment with shellﬁsh extracts spiked with TTX.
Effects in mice occurred at oral doses more than 30-fold higher than the lowest dose reported to
cause serious toxicity in humans (4 lg/kg bw). This suggests considerable interspecies differences
between mice and humans, and between humans. As such, the applied uncertainty factors amounting
to 100, do not necessarily lead to an overestimation of the risk.
The CONTAM Panel noted that the derivation of relative potencies for TTX analogues is associated
with a high level of uncertainty since the underlying methods and data are poorly described.
Due to the fact that there are no occurrence data on TTX and its analogues in European marine
gastropods and no consumption data, these could not be included in the exposure assessment and
therefore constitutes an uncertainty.
Because of the low number of consumption surveys, 5 out of 29, that allowed an estimation of the
P95, the 95th exposures might be underestimated. Application of a 400 g portion size could both over-
or underestimate the high exposure.
There is insufﬁcient information about the distribution of TTX and its analogues in the different
tissues of bivalves (i.e. digestive gland versus whole ﬂesh). Therefore, the CONTAM Panel could not
take potential differences into account. There is also insufﬁcient information about the variation in TTX
levels between individual animals but it can be assumed that these differ signiﬁcantly. However, a large
portion size contains a large number of individual shellﬁsh and as such may average out individual
differences. This may not be the case for smaller portions.
In the exposure assessment, occurrence data from samples collected following different sampling
strategies are included. This could have led to the inclusion of non-representative samples meaning
that the average and P95 levels are higher than if only samples from objective sampling would have
been used leading to an overestimation of the actual exposures.
Due to a low number of quantiﬁed levels of TTX analogues, the relatively low levels of TTX
analogues as compared to TTX when detected and the low relative potencies of the analogues
detected, these were not included in the exposure assessment. This may lead to a small
underestimation of the exposure.
The occurrence data used in the exposure assessment came predominantly from the UK, and to a
minor extent from the Netherlands and Greece and are therefore not representative for the EU which
could have led to both an over or underestimation of the exposure. Additional occurrence data from
the UK (Northern Ireland) and France could not be considered in the present exposure assessment
because they were submitted late. As all the samples were non-detects, their inclusion would have
resulted in lower TTX exposure.
Not for all edible bivalves and gastropods, consumption data are included in the EFSA
Comprehensive Consumption database leading to an underestimation of the overall exposure.
3.7.1. Summary of the main uncertainties
In Table 17 a summary of the uncertainty evaluation is presented.
Table 17: Evaluation of the main uncertainties impacting the assessment
Sources of uncertainty Direction(a)
Derivation of an ARfD based on mouse data +/
Non-inclusion of marine gastropods in the exposure assessment 
Non-inclusion of TTX analogues in the exposure assessment 
Relative potencies for TTX and some of its analogues +/
Occurrence data not representative for the EU +/
Non representative sampling strategy +
Assumption of a 400 g portion size +/
P95 exposure estimation based on only few consumption surveys 
(a): + = uncertainty with potential to cause overestimation of exposure/risk;  = uncertainty with potential to cause
underestimation of exposure/risk, +/ = extent of potential over/underestimation might differ in direction.
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The overall uncertainty associated with the present assessment is considered as high and it would
rather overestimate than underestimate the risk.
4. Conclusions
4.1. Introduction
TTX is a hydrophilic heat-stable toxin, produced by bacteria that can be found in certain ﬁsh
species but also marine gastropods and bivalves. Recently, TTX and some of its analogues have been
detected in gastropods and bivalves from European waters. There are no HBGVs for TTX worldwide
and also no maximum levels in seafood in the EU. TTX is a sodium channel blocker and can cause
serious poisoning and even death after ingestion. Altogether, 25 naturally occurring analogues of TTX
have been detected and many of these have also been shown to have toxicity potential. TTX is
positively charged in neutral solutions. Under acidic conditions, TTX exists as a mixture in equilibrium
with the ortho ester, the lactone form, 4-epiTTX and 4,9-anhydroTTX.
4.2. Analytical methods
• The MBA is the most widely applied detection method for TTXs outside the EU. However, the
test cannot discriminate between TTXs and STXs.
• Cell-based assays are an alternative to the mouse bioassay but likewise cannot discriminate
between TTXs and STXs.
• Immunoassays are more speciﬁc towards TTX but less suitable for screening for analogues,
since their detection depends on cross-reactivity. When detected, this may not be according to
the toxic potencies.
• The MBA and cell-based assays can be used to show the absence of TTXs and STXs but in
case of positive test results, only chemical-analytical methods can identify the toxins and their
analogues.
• Chemical-analytical methods, in particular LC–MS/MS, are the most suitable detection methods
because they allow identiﬁcation and quantiﬁcation of TTX and its analogues. STXs may be
included in the same analysis. LOQs for TTX and analogues in marine bivalves, as reported by
three Member States, vary between 0.1 and 25 lg/kg.
4.3. Toxicokinetics
• There is very little information on toxicokinetics of TTXs in laboratory animals. In the case of
mice, LD50 values for i.p. treatment are 25–50-fold lower than for oral treatment. This was also
observed for STX.
• There is limited information about absorption and excretion of TTX and its analogues in
humans and no information has been identiﬁed on its distribution and metabolism. TTX has
been detected in blood and urine of patients for several days after exposure. TTX is assumed
to be rapidly absorbed in the human digestive tract, based on the short time span between
ingestion and onset of the symptoms seen in human poisoning cases.
4.4. Toxicity
• No subchronic or chronic studies on TTX have been identiﬁed.
• TTX is acutely toxic in humans and in experimental animals.
• In experimental animals, effects observed upon acute exposure include skeletal muscle
fasciculations, apathy, lethargy, ataxia, ascending progressive paralysis and death.
• Acute i.p. and s.c. LD50 values in mice range from 9 to 12.5 lg/kg bw. Upon intragastric
application, much higher LD50 values of 232 and 532 lg/kg bw have been identiﬁed.
• In an acute study, apathy was seen in all mice at a doses of 125 lg/kg bw TTX and higher but
in none of the mice at 25 and 75 lg/kg bw upon single dose intragastric treatment. Doses of
250 lg/kg bw and higher resulted in the death of animals within the 2-h observation period.
• TTX is not genotoxic.
• In humans, TTX is a potent neurotoxin, leading to a sequence of acute symptoms from
perioral numbness and paraesthesia, lingual numbness, early motor paralysis, incoordination,
slurred speech to generalised ﬂaccid paralysis, aphonia and ﬁxed/dilated pupils to hypoxia,
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hypotension, bradycardia, cardiac dysrhythmias and unconsciousness. Death is caused by
respiratory failure and cardiac collapse. There is no antidote against TTX poisoning.
• The doses at which TTX causes acute toxicity and lethality in humans are unclear, but there
are a series of human case reports available that indicate that acute poisoning can result from
doses of 4–42 lg/kg bw and higher. In the literature, a MLD of 2 mg per person is often
mentioned (corresponding to 40 lg/kg bw in a 50-kg adult). The source of the MLD and the
underlying data could not be retrieved.
• For TTX analogues, no data are available allowing derivation of NOAELs or LOAELs; however,
LD50 values upon i.p. application have been reported.
4.5. Mode of action
• TTX exhibits its toxicity by extracellular blockade of the channel pore of voltage-gated sodium
channels (Nav). Thus, TTX affects both action potential generation and impulse conduction
resulting in a blockade of the neuron action potential and in muscle paralysis. Affected are the
respiratory system, the diaphragm, skeletal muscles and tissues in the digestive tract.
4.6. Relative potency of TTX and its analogues
• When i.p. injected in mice, many TTX analogues exert similar effects as TTX. Relative
potencies compared to TTX have been estimated for a series of TTX analogues based on these
in vivo tests with mice where lethality was the endpoint and are supported by in vitro tests
with the Neuro-2a bioassay. TTX is more potent than most of its tested analogues.
• The relative potencies for 11-oxoTTX and 11-norTTX-6(R)-ol derived from i.p. LD99 results
compared to LD100 for TTX are 0.75 and 0.17, respectively. Relative potencies derived from i.p.
LD50 values in mice in comparison to TTX are 0.14 for 11-deoxyTTX and 0.19 for 11-norTTX-6
(S)-ol. Relative potencies calculated from lethal potencies in mice are 0.16 for 4-epiTTX and
0.02 for 4,9-anhydroTTX. Relative potency for 5,6,11-deoxyTTX is 0.01 based on comparison
of the MLD with that for TTX.
• The Panel noted that the derivation of relative potencies for TTX analogues is associated with
signiﬁcant uncertainties since underlying methods and data are poorly described.
4.7. Consideration of setting a HBGV
• Based on the pronounced toxicity of TTX upon acute exposure, the CONTAM Panel decided to
derive an ARfD. The use of human data, extrapolation from data on STX and the use of animal
data were considered. Because of the overall limitations of the available human data, these
were not used to derive the ARfD, but only as supportive information. Similar was true for STX
which in humans shows similar effects and in mice similar toxic potency (both after i.p. and
oral treatment) and mode of action as TTX.
• Acute toxicity data on TTX in mice provide an acute LOAEL of 125 lg/kg bw (incidence 9/9
animals), and an acute NOAEL of 75 lg/kg bw based on apathy. However, there is a narrow
interval between the dose where lethality occurred (250 lg/kg bw) and the dose where no
apathy was observed.
• It was not possible to derive a BMD for apathy while lethality could be modelled, resulting in a
BMDL10 of 112 lg/kg bw. This is only slightly above the NOAEL for apathy (75 lg/kg bw).
Furthermore, with a group size of nine individuals at the dose of 75 lg/kg bw, it cannot be
excluded that effects can occur. The next lower dose tested (25 lg/kg bw) was therefore
selected as the reference point to derive an ARfD. This dose is 4.5-fold lower than the BMDL10
for lethality.
• Applying a standard UF of 100, an ARfD of 0.25 lg/kg bw was derived. This ARfD is 16-fold
lower than the dose at which severe effects have been observed in humans (4 lg/kg bw) and
twofold lower than the ARfD for STX (0.5 lg/kg bw).
• The ARfD is a group ARfD that should apply to TTX and its analogues, taking into account
their relative potencies as compared to TTX, calculated to be 0.75 for 11-oxoTTX, 0.14 for 11-
deoxyTTX, 0.19/0.17 for S/R 11-norTTX-(6)-ol, 0.16 for 4-epiTTX, 0.02 for 4,9-anhydroTTX and
0.01 for 5,6,11-deoxyTTX.
• No data on long-term effects of TTX have been identiﬁed, and therefore, a TDI has not been
set for TTX and its analogues.
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4.8. Occurrence data
• A total of 8,268 analytical results for 1,677 samples were submitted to EFSA by the UK, Greece
and the Netherlands. For all samples, analytical results were provided for TTX, whereas only
1,136 analytical results were provided for 4-epiTTX, 1,080 for 5,6,11-trideoxyTTX, 1,080 for
11-norTTX-6-ol, 1,080 for mono-deoxyTTX, 1,135 for 4,9-anhydroTTX and 1,080 for 11-
oxoTTX.
• Samples of bivalves were taken between 2006 and 2016, including mussels, oysters, cockles,
clams, scallops and razor clams. No occurrence data were received for marine gastropods.
• In 92% of the samples, TTX was not detected or quantiﬁed. LOQs on TTX ranged from 1 to
25 lg/kg, where LODs ranged from 0.5 to 5 lg/kg. The UB median and 95th percentile levels
reported to EFSA, taking into consideration all received data on TTX in bivalves were 5.9 and
28 lg/kg, respectively. In most cases, this was based on raw meat, in some cases the
digestive gland.
• For different species of water molluscs, the highest upper bound mean was reported for clams,
10.8 lg/kg and the highest 95th percentile level was reported for oysters, 79 lg/kg.
• TTX analogues were detected in about 1% of the samples.
4.9. Exposure assessment
• Due to the relatively low number of quantiﬁed levels and relatively low levels of TTX analogues
as compared to TTX and the low relative potencies of the analogues, the CONTAM
Panel decided not to include them in the exposure assessment and only TTX data were used.
• Because no occurrence and limited consumption data were available for marine gastropods,
these could not be included in the exposure assessment.
• Acute exposure assessments for TTX were carried out with two different approaches, namely i)
by using the consumption data in the EFSA Comprehensive database applying a probabilistic
approach, and ii) by using a large portion size of 400 g for bivalves.
• In the probabilistic assessment and based on consumption days only, the highest estimated
average acute exposure level of 0.09 lg/kg bw occurred in the ‘elderly’ (based on only two
consumption days) and the highest estimated 95th percentile exposure of 0.03 lg/kg bw in
the elderly, adults and adolescents. However, only ﬁve out of 29 surveys allowed an estimate
of the P95 exposure.
• Regarding the different types of marine bivalves, the highest mean exposure levels from clams,
mussels and oysters were 0.02, 0.03 and 0.09 lg/kg bw, respectively, whereas for razor clams,
scallops, cockles and non-speciﬁed water molluscs, average acute exposure was zero.
• The highest 95th percentile exposure, considering only the consumption days, was estimated
from oysters, being 0.08 lg/kg bw.
• Acute exposures to TTX estimated using a large portion size of 400 g and P95 concentrations
ranged from 0.03 to 0.45 lg/kg bw, depending on the bivalve species.
4.10. Risk characterisation
• The average and 95th percentile acute exposure levels, based on reported consumption did
not exceed the group ARfD of 0.25 lg TTX/kg bw in any of the consumer groups indicating no
general concern for human health due to the consumption of marine bivalves. This also applied
for a 400 g portion size using the 95th percentile occurrence data with exception of oysters for
which the group ARfD was exceeded about twofold.
• It was not possible to include marine gastropods in the risk characterisation because of lack of
data.
• Based on a large portion size (400 g), an adult body weight of 70 kg and a group ARfD of
0.25 lg/kg bw, the CONTAM Panel concluded that a concentration lower than 44 lg of TTX
and/or its equivalent toxic amount of its analogues per kg shellﬁsh meat is not expected to
lead to adverse effects in humans. The Panel noted that the P95 of the occurrence data for all
shellﬁsh is below this value. However, levels above 44 lg/kg have been reported for both
mussels and oysters indicating an occasional concern for consumers of a large portion size of
400 g or larger.
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5. Recommendations
• More occurrence data on TTX and its analogues in edible parts of marine bivalves and
gastropods from different EU waters are needed to provide a more reliable exposure
assessment.
• Occurrence data on marine gastropods are needed from different EU Member States.
• Data on concentrations of TTX and its analogues should be obtained using EU approved and
validated chemical-analytical methods. In addition, certiﬁed standards and reference materials
for TTX and analogues are needed.
• Information on the fate of TTX and its analogues during cooking is needed to reﬁne exposure
assessments.
• Studies on the sources and critical factors leading to the accumulation of TTX in marine
bivalves and gastropods are needed.
• Further information on toxicokinetics of TTX and its analogues is needed.
• Further information on the acute oral toxicity of TTX and its analogues is needed. Chronic
effects should also be investigated.
• Given the high uncertainties associated with derivation of the relative potencies of TTX
analogues, adequate and well described evidence is needed to estimate their relative
potencies, preferentially after oral exposure.
• As STX and TTX exert similar toxic effects via a similar mode of action, the possibility to
combine STX and its analogues together with TTX and its analogues in one HBGV should be
explored.
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c-GTP gamma-glutamyl transpeptidase
ALP alkaline phosphatase
ALS aldolase
ALT alanine aminotransferase
API atmospheric pressured ionisation
ARfD acute reference dose
ASP amnesic shellﬁsh poisoning
BMD benchmark dose
Cav voltage-gated calcium channel
CAS Chemical Abstracts Service
CAM cell adhesion molecules
cDNA complementary DNA
CHO Chinese hamster ovary cells
CONTAM Panel EFSA Panel on contaminants in the food chaiin
DG digestive gland
ED50 effective dose 50%
ELISA enzyme-linked immunosorbent assay
ESI electrospray ionisation
EURLMB European reference laboratory for marine biotoxins
FAO Food and Agriculture Organization of the United Nations
FAVV Federal Agency for the Safety of the Food Chain
FSA Food Standards Agency
GC gas chromatography
GLP good laboratory practice
GTX-3 grayanotoxin 3
HILIC hydrophilic interaction chromatography
hNav human voltage-gated sodium channel
HSDB Hazardous Substances Data Bank
IC50 inhibitory concentration 50%
ICR mouse strain
IFREMER French Research Institute for Exploitation of the Sea
i.p. intraperitoneal
IPCS International Programme on Chemical Safety
ISO The International Organization for Standardization
i.v. intravenous
JECFA Joint FAO/WHO Expert Committee on Food Additives
Kv voltage-gated potassium channel
LB lower bound
LC liquid chromatography
LC-FL liquid chromatography with ﬂuorescence detection
LC–ESI–MRM-MS liquid chromatography–electrospray ionisation–multiple reaction monitoring-mass
spectrometry
LC-HRMS liquid chromatography-high resolution mass spectrometry
LC–MS liquid chromatography with mass spectroscopy
LC–MS/MS liquid chromatography with tandem mass spectroscopy
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LD50 lethal dose 50%
LD99 lethal dose 99%
LD100 lethal dose 100%
LDH lactate dehydrogenase
LOAEL lowest observed adverse effect level
LOD limit of detection
LOQ limit of quantiﬁcation
MB medium bound
MBA mouse bioassay
MLD minimum lethal dose
MRM multiple reaction monitoring
MS mass spectroscopy
MU mouse unit
MW molecular weight
m/z mass-to-charge ratio
N2a-assay bioassay with neuro-2a cells
Nav voltage-gated sodium channel
NMR nuclear magnetic resonance
NOAEL no observed adverse effect level
NVWA-BuRO Netherlands Food and Consumer Product Safety Authority - Department for Risk
Assessment & Research
OECD Organisation for Economic Co-Operation and Development
O/V ouabain/veratridine
PSP paralytic shellﬁsh poisoning
QSAR quantitative structure–activity relationship
RIVM National Institute for Public Health
rNav rat voltage-gated sodium channel
RP relative potency
s.c. subcutaneous
SCF Scientiﬁc Committee on Food
SOP standard operational procedure
SPR surface plasmon resonance
STX saxitoxin
TDI tolerable daily intake
TEF toxic equivalency factor
TLC thin-layer chromatography
ToR Term of Reference
TTC threshold of toxicological concern
TTX tetrodotoxin
TTX-s TTX-sensitive
TTX-r TTX-resistant
UB upper bound
UDS unscheduled DNA synthesis
UPLC ultra performance liquid chromatography
UPLC–MS/MS ultra performance liquid chromatography - tandem mass spectrometer
WF whole ﬂesh
WHO World Health Organization
w/w weight/weight
ZIC zwitterionic hydrophilic interaction chromatography- hydrophilic interaction
chromatography
TTX in marine bivalves and gastropods
www.efsa.europa.eu/efsajournal 55 EFSA Journal 2017;15(4):4752
Appendix A – Identiﬁcation and selection of relevant scientiﬁc literature
and reports
Analytical methods
Search terms TOPIC: (Tetrodotoxin OR TTX) AND TOPIC: (chem* OR analy* OR identi* OR
charact* OR detect* OR determin* OR method* OR GC OR HPLC OR LC-MS OR
ICP-MS) AND TOPIC: (animal* OR bivalve OR mollusc* OR gastropo* OR Marine*
OR Fish OR Organism*) NOT TOPIC: (frog OR newt OR worm OR crab OR
terrestrial OR star ﬁsh OR star ﬁsh OR salamander OR sea slug OR zebraﬁsh OR
cats OR jellyﬁsh OR rat OR mouse OR monkey OR dog OR horse)
Numbers of papers retrieved 336
Occurrence
Search terms TOPIC:(Tetrodotoxin OR TTX) AND TOPIC: (concentration* OR occurrence) AND
TOPIC: (Bivalve* OR Mollusc* OR Mussel OR clams OR oysters OR cockles OR
scallops OR Gastropo* OR nassariid* OR snail* OR Gibulla OR Charonia OR
octopus* OR squid OR cuttleﬁsh OR mantle)
Numbers of papers retrieved 51
Metabolism, Kinetics
Search terms TOPIC: (Tetrodotoxin OR TTX) AND TOPIC: (toxicokinetic* OR metabolism OR
distribution OR excretion OR absorption OR distribution OR biomarker OR mode of
action OR biotransformation OR elimination OR reduction OR detoxiﬁcation OR
extraction) Reﬁned by: [excluding] WEB OF SCIENCE CATEGORIES:
(NEUROSCIENCES OR PHYSIOLOGY)
Numbers of papers retrieved 458
Toxicity
Search terms TOPIC: (Tetrodotoxin OR TTX) AND TOPIC: (acute OR chronic OR tox* OR
genotox* OR muta* OR DNA OR damage OR repair OR clastogen* OR aneugen*
OR chromosom* OR cancer* OR carcino* OR tumor* OR tumour* OR organ* OR
tissue* OR immun* OR neuro* OR developmental OR teratogen* OR repro* OR
liver OR kidney* OR brain* OR lung* OR cardiovascular OR rat* OR mouse OR
mice OR rabbit* OR hamster* OR primate* OR monkey*)
Reﬁned by: [excluding] WEB OF SCIENCE CATEGORIES: (NEUROSCIENCES OR
PHYSIOLOGY) AND [excluding] DOCUMENT TYPES: (PROCEEDINGS PAPER OR
MEETING ABSTRACT)
Numbers of papers retrieved 5,467
Epidemiology
Search terms TOPIC: (Tetrodotoxin OR TTX) AND TOPIC: (epidemio* OR exposure* OR case*
OR poison* OR cross-sectional)
Reﬁned by: [excluding] WEB OF SCIENCE CATEGORIES: (NEUROSCIENCES OR
PHYSIOLOGY)
Numbers of papers retrieved 454
Database used Web of Science
Total Number Retrieved 6,766
Number after duplicates
removed
2,704
Number considered
relevant
411
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Appendix D – Derivation of a BMD for acute effects of TTX applying a BMR10
A. Data description
The dose-dependent lethality observed within 2 h upon intragastric administration of TTX to mice in
the study from Abal et al. (2017) has been selected for derivation of a benchmark dose (BMD) for TTX
following EFSA guidance on the use of the BMD (EFSA Scientiﬁc Committee, 2017). The ﬁndings
selected for deriving a BMD are described in Section 3.2.2 of this opinion.
Substance Dose (lg/kg bw) Dead animals N Sex
TTX 25 0 9 F
75 0 9 F
125 0 9 F
250 4 7 F
500 4 5 F
1,000 3 3 F
N: number of animals; bw: body weight.
B. Selection of the BMR:
The BMD is deﬁned as the dose that corresponds with an extra risk of 10% compared with the
background risk. The benchmark response (BMR) is the estimated risk corresponding with the BMD of
interest. A 90% conﬁdence interval around the BMD will be estimated, the lower bound is reported by
BMDL and the upper bound by BMDU. Based on the number of animals, it was decided to apply a
BMD10 and not a BMD01, despite the severity of the endpoint.
C. Software used:
Results are obtained using the R-package ‘bmdModeling’. Fitting BMD models is based on the R-
package Proast 61.3. Averaging results from multiple ﬁtted BMD models is based on the methodology
in Wheeler and Bailer (2008).
D. Results
Model
Number of
parameters
Log-
likelihood
AIC BMD BMDL BMDU Converged
Accepted
AIC
Null 1 24.15 50.30 NA NA NA Yes
Full 6 7.28 26.56 NA NA NA Yes
Logistic 2 10.01 24.02 159.94 103.38 228.63 Yes Yes
Log-
logistic
3 8.43 22.86 153.78 95.16 211.13 Yes Yes
Log-probit 3 8.28 22.56 154.43 97.46 212.34 Yes Yes
Weibull 3 9.16 24.32 142.30 77.47 214.42 Yes Yes
Gamma 3 8.64 23.28 152.71 89.35 214.54 Yes Yes
Two-stage 3 9.35 24.70 120.61 90.48 167.64 No No
Alerts that were indicated when ﬁtting the models: Errors in calculation: Null, Probit model: need at
least two non-NA values to interpolate.
Estimated model weights
Logistic Log-logistic Log-probit Weibull Gamma
0.14 0.25 0.29 0.12 0.2
TTX in marine bivalves and gastropods
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G. Conclusion
Given the 500 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD
values and the BMDU is the 95th percentile.
Estimated the BMD based on the averaged response model which is a weighted average of the
accepted models’ response values.
BMD = 153.23 lg/kg bw; BMDL = 112.12 lg/kg bw; BMDU = 246.59 lg/kg bw.
Figure D.1: Average response model
TTX in marine bivalves and gastropods
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Annex A – TTX Consumption data
Annex A can be found in the online version of this output (‘Supporting information’ section): http://
onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4752/abstract
Description: TTX Consumption data – excel ﬁle
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Annex B – TTX Acute exposure individuals
Annex B can be found in the online version of this output (‘Supporting information’ section): http://
onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4752/abstract
Description: TTX Acute exposure individuals – excel ﬁle
TTX in marine bivalves and gastropods
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